Hepatitis B

Infectious Disease MONDO:0005344 Pathograph 6 Viral Infection

Hepatitis B is a viral infection caused by Hepatitis B Virus (HBV) that primarily affects the liver. It can cause both acute and chronic disease, with chronic infection leading to cirrhosis, liver failure, and hepatocellular carcinoma. Transmission occurs through blood, sexual contact, and from mother to child during birth.

Ask OpenScientist

Ask a research question about Hepatitis B. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

6
Pathophys.
10
Phenotypes
6
Pathograph
1
Genes
5
Treatments
2
Deep Research
⚙

Pathophysiology

6
Hepatocyte Infection and cccDNA Formation
HBV enters hepatocytes via NTCP receptor binding, and viral rcDNA is converted to covalently closed circular DNA (cccDNA) which forms a stable chromatinized minichromosome in the nucleus, enabling persistent infection.
Hepatocyte link
viral entry into host cell link epigenetic regulation of gene expression link
liver link
Downstream
Chronic Inflammation HBV infection triggers persistent immune activation and hepatic inflammation through both innate and adaptive immune responses.
HBV DNA Integration A fraction of viral DNA integrates into host genome at sites of DNA damage, contributing to persistent HBsAg expression and oncogenesis.
Show evidence (4 references)
PMID:33573130 PARTIAL
"Human hepatitis B virus (HBV) can cause chronic, lifelong infection of the liver that may lead to persistent or episodic immune-mediated inflammation against virus-infected hepatocytes."
This reference confirms that HBV infects hepatocytes and leads to chronic inflammation.
PMID:32866519 PARTIAL
"'Hepatitis B virus (HBV) specifically infects hepatocytes and causes severe liver diseases."
This reference confirms that HBV specifically infects hepatocytes.
PMID:30518652 PARTIAL
"Distinct populations of hepatocytes infected with hepatitis B virus (HBV) or only harboring HBV DNA integrations coexist within an HBV chronically infected liver."
This reference confirms that HBV integrates into the host genome within hepatocytes and persists.
+ 1 more reference
HBV DNA Integration
Integration of viral dslDNA into host genome occurs at sites of DNA damage, driving insertional mutagenesis, structural rearrangements, and activation of proto-oncogenes.
DNA integration link
Downstream
Hepatocellular Carcinoma DNA integration drives oncogenesis through activation of TERT and other proto-oncogenes, genomic instability, and structural rearrangements.
Chronic Inflammation
Persistent immune response against HBV-infected hepatocytes leads to liver damage mediated by T cells, NK cells, and Kupffer cells.
CD8-positive, alpha-beta T cell link natural killer cell link inflammatory macrophage link
Downstream
Liver Fibrosis Chronic inflammation activates hepatic stellate cells leading to extracellular matrix deposition and progressive fibrosis.
Cirrhosis Progressive fibrosis leads to architectural disruption and nodule formation characteristic of cirrhosis.
Show evidence (5 references)
PMID:8571172 SUPPORT
"The immune response to HBV-encoded antigens is responsible both for viral clearance and for disease pathogenesis during this infection."
This reference supports that the immune response against HBV-infected hepatocytes contributes to liver damage, which aligns with the statement.
PMID:34543610 PARTIAL
"Cirrhosis is widely prevalent worldwide and can be a consequence of different causes, such as... hepatitis B or C infection."
This reference supports the link between chronic HBV infection and cirrhosis, which is a downstream effect of persistent immune response and liver damage.
PMID:32147592 PARTIAL
"Progression of liver fibrosis still occurs in some patients with chronic hepatitis B virus (HBV) infection despite antiviral therapy."
This reference supports that chronic HBV infection leads to liver fibrosis, which is a downstream effect of immune response and liver damage.
+ 2 more references
Immune Evasion and T Cell Exhaustion
HBV evades innate immune detection through dampened TLR, cGAS-STING, and RIG-I-MAVS pathways. Chronic infection leads to T cell exhaustion with upregulation of PD-1, CTLA-4, and TIM-3 checkpoint receptors.
CD8-positive, alpha-beta T cell link regulatory T cell link
negative regulation of T cell activation link cGAS-STING signaling pathway link
Show evidence (2 references)
PMID:16461223 NO_EVIDENCE
"The immune system plays an important role in determining the outcome of hepatitis B virus (HBV) infection... Multispecific antiviral CD4 and CD8 responses with a type 1 cytokine production can be observed in patients who recover from acute HBV infection."
The reference supports the role of T cells in immune clearance but does not mention B cells.
PMID:36936922 NO_EVIDENCE
"The clearance of HBV with virus-specific CD8 T cells is critical for a functional cure."
The reference supports the role of T cells in immune clearance but does not mention B cells.
Liver Fibrosis
Chronic inflammation promotes fibrotic tissue deposition replacing healthy liver cells.
Downstream
Cirrhosis Progressive fibrosis leads to complete architectural disruption and end-stage liver disease.
Show evidence (4 references)
PMID:17613356 SUPPORT
"Liver fibrosis results from chronic damage to the liver in conjunction with the progressive accumulation of fibrillar extracellular matrix proteins."
The statement is supported as liver fibrosis involves the replacement of healthy liver cells with fibrotic tissue due to chronic inflammation.
PMID:33528280 SUPPORT
"Chronic inflammation involves CCL11 and IL-13 to facilitate the development of liver cirrhosis and fibrosis in chronic hepatitis B virus infection."
The statement is supported as chronic inflammation promotes liver fibrosis through specific inflammatory pathways.
PMID:26691189 SUPPORT
"Chronic unresolved inflammation is associated with persistent hepatic injury and concurrent regeneration, leading to sequential development of fibrosis, cirrhosis, and eventually HCC."
The statement is supported as chronic inflammation leads to liver fibrosis and cirrhosis.
+ 1 more reference
Cirrhosis
Extensive fibrosis and scarring significantly impair liver function.
Show evidence (4 references)
PMID:17981234 SUPPORT
"Untreated, chronic hepatitis B acquired early in life results in cirrhosis, liver failure, or hepatocellular carcinoma in up to 40% of individuals."
This reference supports the statement by indicating that chronic hepatitis B can lead to cirrhosis, which is associated with extensive fibrosis and scarring that impair liver function.
PMID:19577114 SUPPORT
"Cirrhosis is defined histologically as an advanced form of progressive hepatic fibrosis with distortion of the hepatic architecture and regenerative nodule formation."
This reference supports the statement by describing cirrhosis as an advanced form of hepatic fibrosis that distorts liver architecture, thereby impairing liver function.
PMID:17613356 PARTIAL
"Liver fibrosis results from chronic damage to the liver in conjunction with the progressive accumulation of fibrillar extracellular matrix proteins."
While this reference discusses liver fibrosis resulting from chronic liver damage, it does not explicitly connect it to cirrhosis or the impairment of liver function.
+ 1 more reference
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Referential integrity issues (1):
  • Target 'Hepatocellular Carcinoma' (from 'HBV DNA Integration') not found in named elements
Pathograph: causal mechanism network for Hepatitis B Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Digestive 4
Jaundice FREQUENT Jaundice (HP:0000952)
Due to liver dysfunction causing elevated bilirubin levels
Show evidence (4 references)
PMID:24266913 NO_EVIDENCE
"Chronically infected patients should be followed on a regular basis, preferably every 6 months, with liver function tests, and when appropriate, HBV DNA levels. Those who meet the criteria for high risk for HCC should undergo liver ultrasound every 6 months. Powerful antiviral medications are..."
The literature mentions the management of chronic Hepatitis B and its effects on liver function, which can lead to jaundice.
PMID:3050928 SUPPORT
"The classic presenting symptoms of viral hepatitis are jaundice, nausea, vomiting, malaise, anorexia, and dull right upper quadrant pain."
The literature explicitly lists jaundice as a classic presenting symptom of viral hepatitis, including Hepatitis B.
PMID:34835022 PARTIAL
"Hepatitis B virus (HBV) infection is one of the serious health problems in the world as HBV causes severe liver diseases."
The literature discusses the severe liver diseases caused by Hepatitis B, which can lead to jaundice due to liver dysfunction.
+ 1 more reference
Nausea FREQUENT Nausea (HP:0002018)
Show evidence (1 reference)
PMID:3050928 SUPPORT
"The classic presenting symptoms of viral hepatitis are jaundice, nausea, vomiting, malaise, anorexia, and dull right upper quadrant pain."
The literature explicitly mentions nausea as a classic presenting symptom of viral hepatitis, which includes Hepatitis B.
Vomiting FREQUENT Vomiting (HP:0002013)
Show evidence (1 reference)
PMID:3050928 PARTIAL
"The classic presenting symptoms of viral hepatitis are jaundice, nausea, vomiting, malaise, anorexia, and dull right upper quadrant pain."
The reference mentions vomiting as one of the classic presenting symptoms of viral hepatitis, which includes Hepatitis B. However, it does not specify the frequency, so it partially supports the statement.
Hepatomegaly OCCASIONAL Hepatomegaly (HP:0002240)
Liver enlargement
Show evidence (2 references)
PMID:12150847 NO_EVIDENCE
"Occult hepatitis B occurs in a number of clinical settings."
While the abstract does not specifically mention hepatomegaly as a frequent symptom, it implies that various liver-related conditions are associated with hepatitis B, supporting the occasional occurrence of hepatomegaly.
PMID:19682192 PARTIAL
"Severe acute exacerbation is a unique presentation of chronic hepatitis B characterized by very high alanine aminotransferase level accompanied by jaundice and hepatic decompensation."
The text describes severe liver conditions related to chronic hepatitis B, but does not directly mention hepatomegaly. It suggests severe liver involvement, which could include hepatomegaly.
Immune 1
Rash OCCASIONAL Skin rash (HP:0000988)
Show evidence (3 references)
PMID:6133886 PARTIAL
"Dermatologic manifestations of hepatitis B virus infection."
The title of the reference directly indicates the presence of dermatologic manifestations, supporting the statement that hepatitis B can cause occasional dermatologic conditions like rash.
PMID:1185334 SUPPORT
"The association of arthritis, arthralgia, and various types of skin rashes, as a prodrome to viral hepatitis, although well recognized in adults, has not been well described in children."
The reference mentions that skin rashes are recognized as prodromal manifestations of viral hepatitis, including hepatitis B, supporting the statement.
PMID:1532114 NO_EVIDENCE
"The most frequent adverse reactions were myalgia/arthralgia lasting longer than 3 days (14), followed by skin rashes (eight) and dizziness (seven)."
The reference notes that skin rashes were among the most frequent adverse reactions to the hepatitis B vaccine, indicating that hepatitis B can be associated with dermatologic manifestations like rash.
Metabolism 1
Fever OCCASIONAL Fever (HP:0001945)
Show evidence (3 references)
PMID:28223176 PARTIAL
"Prodromal fever indicated more severe liver injury and was independently associated with hepatitis B e antigen (HBeAg) negativity."
The study indicates that fever can be associated with acute hepatitis B, particularly in severe cases, but it does not explicitly categorize fever as an occasional systemic manifestation.
PMID:34913875 PARTIAL
"Several of these extrahepatic syndromes have been well described, including systemic vasculitides, glomerulonephritis, and cutaneous manifestations."
While the reference mentions systemic manifestations of hepatitis B, it does not specifically mention fever as one of them.
PMID:35499229 PARTIAL
"The study confirms the endemicity of hepatitis B and enteric fever in the area."
The study mentions the prevalence of hepatitis B among febrile patients but does not specifically categorize fever as an occasional systemic manifestation of hepatitis B.
Constitutional 3
Fatigue FREQUENT Fatigue (HP:0012378)
Show evidence (1 reference)
PMID:7493307 SUPPORT
"Hepatitis cases scored significantly higher fatigue scores, GHQ-12 scores and muscle pain scores."
The study indicates that fatigue is more common after recovery in patients hospitalized for hepatitis B up to 30 months post-infection compared with matched controls hospitalized for other infectious diseases.
Abdominal Pain OCCASIONAL Abdominal pain (HP:0002027)
May be related to liver inflammation
Show evidence (2 references)
PMID:24954675 NO_EVIDENCE
"Hepatitis B virus is not cytopathic; both liver damage and viral control--and therefore clinical outcome--depend on the complex interplay between virus replication and host immune response."
The literature mentions liver damage and clinical outcomes related to Hepatitis B, which can include gastrointestinal symptoms like abdominal pain due to liver inflammation.
PMID:3050928 SUPPORT
"The classic presenting symptoms of viral hepatitis are jaundice, nausea, vomiting, malaise, anorexia, and dull right upper quadrant pain."
The literature lists dull right upper quadrant pain as a classic symptom of viral hepatitis, which includes Hepatitis B, supporting the statement that abdominal pain is an occasional gastrointestinal symptom related to liver inflammation.
Arthralgias OCCASIONAL Arthralgia (HP:0002829)
Joint pain
Show evidence (1 reference)
PMID:18760074 SUPPORT
"The most commonly described include skin rash, arthritis, arthralgia, glomerulonephritis, polyarteritis nodosa, and papular acrodermatitis etc."
The reference confirms that arthralgia (joint pain) is a commonly described extrahepatic manifestation of Hepatitis B.
Other 1
Elevated Liver Enzymes VERY_FREQUENT
Reflects liver cell damage and is a key diagnostic feature
Show evidence (5 references)
PMID:34835022 SUPPORT
"The HBV surface antigen (HBsAg)-positive group had a more frequent prevalence of patients with higher transaminase elevations than the HBsAg-negative group."
The study indicates that elevated liver enzymes, which reflect liver cell damage, are more frequently observed in patients with Hepatitis B virus infection.
PMID:30418344 PARTIAL
"Abnormal liver enzymes are frequently encountered in primary care offices and hospitals and may be caused by a wide variety of conditions, from mild and nonspecific to well-defined and life-threatening."
Elevated liver enzymes are a common diagnostic feature in various liver diseases, including Hepatitis B.
PMID:29551632 NO_EVIDENCE
"The prevalence of hepatitis B surface antigen (HBsAg) was 18.5% (126/680) and of liver cirrhosis was 9.4% (64/680)."
The presence of elevated liver enzymes is associated with Hepatitis B infection, as indicated by the prevalence of HBsAg in patients.
+ 2 more references
🧬

Genetic Associations

1
HBV Genotype
Show evidence (3 references)
PMID:19072424 SUPPORT
"There are eight different genotypes named A-H. Genotypes have distinct geographic distribution in different regions of the world. There exists a difference in the disease profile between different genotypes."
The reference supports the presence of multiple HBV genotypes (A-H) and indicates that these genotypes influence disease progression and treatment response.
PMID:26255971 SUPPORT
"The clinical course of hepatitis B virus (HBV) infection greatly differs in individuals. Various viral, host, and environmental factors influence the natural history of HBV infection."
The reference supports the influence of various factors, including viral genotypes, on the clinical course of HBV infection.
PMID:34593148 SUPPORT
"Various HBV genotypes and their impact on the clinical course are discussed. The relationship of HBV serologies and HBV DNA to disease progression is outlined."
The reference supports the statement that different HBV genotypes influence disease progression and treatment response.
💊

Treatments

5
Antiviral Medications
Action: antiviral therapy Ontology label: antiviral agent therapy MAXO:0000168
Includes drugs like tenofovir and entecavir to suppress HBV replication.
Show evidence (4 references)
PMID:26732483 SUPPORT
"Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have been recommended as the first-line anti-HBV drugs for excellent viral suppression with a low risk of antiviral resistance."
The reference explicitly mentions tenofovir and entecavir as first-line drugs for suppressing HBV replication.
PMID:26054819 SUPPORT
"Since 2008, it has also been indicated for treatment of chronic HBV infection or HIV/HBV co-infection. The aim of the treatment consists in suppressing viral replication, thus reducing hepatic complications and improving patient survival."
The reference supports the use of tenofovir for suppressing HBV replication.
PMID:32050881 SUPPORT
"The aim of this study was to evaluate the histological, virological, serological and biochemical response rates in CHB patients receiving tenofovir or entecavir therapy."
The study evaluates the effects of tenofovir and entecavir in CHB patients, supporting their role in HBV suppression.
+ 1 more reference
Interferon Therapy
Action: immunotherapy Ontology label: Immunotherapy NCIT:C15262
Boosts the immune system to fight the virus.
Show evidence (3 references)
PMID:25034484 PARTIAL
"Interferon-alpha (IFN-alpha) therapy can convert CHB into inactive hepatitis B virus (HBV) infection in 20-30% of the treated patients...IFN-alpha has multiple antiviral, antiproliferative, and immunomodulatory activities."
The literature indicates that Interferon-alpha has immunomodulatory activities, which can help in controlling HBV infection, but it does not explicitly state that it 'boosts' the immune system in the general sense.
PMID:16461223 PARTIAL
"Therapeutic strategies aimed at correcting this defective T cell reactivity could represent a complementary approach to the cure of chronic HBV infection."
The literature suggests that targeting immune responses is a strategy in treating HBV, but it does not explicitly state that Interferon Therapy 'boosts' the immune system.
PMID:10804945 PARTIAL
"We found IFN to be a safe and adequate mode of treatment in children with chronic HBV infection, regardless of their liver histology and transaminase levels."
The study indicates that Interferon Therapy is effective in treating HBV in children, but it does not explicitly state that it 'boosts' the immune system.
Liver Transplant
Action: organ transplantation MAXO:0010039
For end-stage liver disease.
Show evidence (2 references)
PMID:29125261 SUPPORT
"Liver transplantation (LT) is the only effective treatment for hepatitis B-virus (HBV) related end stage liver disease..."
This reference explicitly states that liver transplantation is the only effective treatment for end-stage liver disease caused by hepatitis B.
PMID:17981234 PARTIAL
"Until recently, the options for a patient who had end-stage hepatitis B cirrhosis were severely limited, but during the past 15 years great strides have been made in prevention and treatment of hepatitis B cirrhosis."
The reference discusses the advancements in treatment options for end-stage hepatitis B cirrhosis, implying liver transplantation as a viable option.
Regular Monitoring
Monitoring liver function and viral load to manage chronic infection.
Show evidence (6 references)
PMID:24266913 SUPPORT
"Chronically infected patients should be followed on a regular basis, preferably every 6 months, with liver function tests, and when appropriate, HBV DNA levels."
The literature supports regular monitoring of liver function and viral load in patients with chronic hepatitis B infection.
PMID:12776281 PARTIAL
"Periodic testing for HBV DNA to assess the virological status of HBsAg-positive dialysis patients is recommended."
The study recommends regular monitoring of viral load in hepatitis B patients, supporting the statement.
PMID:33467927 PARTIAL
"This manuscript summarized traditional biomarkers of different hepatitis B stages and recent-developed POCT platforms (including microfluidic platforms and lateral-flow strips) and discuss the challenges associated with their use."
The article discusses the importance of monitoring hepatitis B using various biomarkers, which aligns with the statement.
+ 3 more references
Vaccination
Action: vaccination MAXO:0001017
Hepatitis B vaccine provides prevention for uninfected individuals.
Show evidence (5 references)
PMID:10776195 SUPPORT
"Immunization of all newborn infants and adolescents for HBV is a vital step toward eradicating HBV from the general population."
The article supports the statement by emphasizing the importance of immunizing infants and adolescents to prevent HBV infection.
PMID:33200362 SUPPORT
"Primary prevention by HBV vaccination targeting the general population starting from birth dose."
The article confirms that HBV vaccination is a primary prevention strategy for the general population.
PMID:17298912 SUPPORT
"Hepatitis B vaccines have been licensed since 1982... Long-term protection has been demonstrated."
The article discusses the long-term protection conferred by hepatitis B vaccines, supporting their role in preventing HBV infection.
+ 2 more references
🌍

Environmental Factors

2
Poor Sterile Practices
healthcare facility link
Increases the risk of transmission via medical procedures
Inadequate infection control in healthcare settings increases HBV transmission through contaminated needles, surgical instruments, and blood products.
Show evidence (3 references)
PMID:20123446 SUPPORT
"Increasing recognition of outbreaks involving patient-to-patient spread of hepatitis B and hepatitis C virus infections, however, has uncovered a disturbing trend. This article highlights the importance of basic infection control and the need for increased awareness of safe injection practices."
The article indicates that poor sterile practices can lead to patient-to-patient spread of hepatitis B, supporting the statement that poor sterile practices increase the risk of transmission via medical procedures.
PMID:10840606 SUPPORT
"Cases with the highest number of transmissions (one anesthesiologist with 217 HC transmissions, and one EEG technologist with 75 HB transmissions) were attributed to poor infection control practices."
The report documents numerous cases of hepatitis B transmission attributed to poor infection control practices, supporting the statement.
PMID:23074317 SUPPORT
"We documented HBV transmission during orthopedic surgery to 2 patients from a surgeon with HBV. This investigation highlights the importance of evaluating individuals who do not respond to 2 series of HBV vaccination, the increased risk of HBV transmission from providers with high viral loads,..."
The study demonstrates that poor sterile practices and high viral loads in healthcare providers can lead to the transmission of hepatitis B during medical procedures.
High-risk Behaviors
Includes unprotected sexual contact and intravenous drug use
Behavioral risk factors including unprotected sexual intercourse, intravenous drug use with shared needles, and occupational exposure to blood.
Show evidence (4 references)
PMID:2183516 SUPPORT
"In the Western world most cases of hepatitis B virus (HBV) infection are acquired through sexual intercourse and through needle sharing by intravenous drug users (IVDU)."
The literature explicitly mentions that HBV infection is commonly acquired through sexual intercourse and needle sharing, which aligns with the statement's mention of unprotected sexual contact and intravenous drug use as high-risk behaviors.
PMID:20411413 NO_EVIDENCE
"Sex with multiple partners, sex under the influence of alcohol or drugs, and unprotected sex were the most prevalent HIV risk behaviors."
Although this reference primarily discusses HIV, it also notes that unprotected sex is a prevalent risk behavior, which supports the statement regarding high-risk behaviors for HBV.
PMID:32338365 SUPPORT
"People who inject drugs (PWIDs) are prone to a number of blood-borne viral infections. Hepatitis B virus (HBV) and hepatitis C virus (HCV) constitute an important public health concern in this high risk group."
The literature states that people who inject drugs are at high risk for HBV, supporting the statement that intravenous drug use is a high-risk behavior for HBV.
+ 1 more reference
🔬

Biochemical Markers

3
Hepatitis B Surface Antigen (HBsAg) (Positive)
Context: Indicates active infection
Show evidence (4 references)
PMID:49464 SUPPORT
"HBsAg in an individual indicates that he harbors the virus of hepatitis B; it may be present in the absence of liver disease or be found in association with both acute and chronic type B hepatitis."
The presence of HBsAg indicates that the individual harbors the hepatitis B virus, which supports the statement that a positive HBsAg indicates an active infection.
PMID:22300111 SUPPORT
"To analyze the epidemiological, clinical, and virological characteristics of patients newly diagnosed with active hepatitis B virus (HBV) infection based on the presence of positive hepatitis B surface antigen (HBsAg)..."
The study focuses on patients newly diagnosed with active HBV infection based on the presence of positive HBsAg, supporting the statement that a positive HBsAg indicates an active infection.
PMID:21692954 SUPPORT
"Serum hepatitis B surface antigen (HBsAg) levels reflect intrahepatic hepatitis B virus (HBV) covalently closed circular DNA and may be a valuable addition to HBV DNA in the management of patients with chronic hepatitis B (CHB)."
The presence of HBsAg reflects the presence of hepatitis B virus, indicating active infection, which supports the statement.
+ 1 more reference
Hepatitis B e Antigen (HBeAg) (Positive)
Context: Indicates active viral replication and high infectivity
Show evidence (4 references)
PMID:12124405 SUPPORT
"The presence of hepatitis B e antigen (HBeAg) in serum indicates active viral replication in hepatocytes."
The study confirms that HBeAg is a surrogate marker for active hepatitis B virus replication.
PMID:21205143 SUPPORT
"HBeAg seropositivity is a marker for active viral replication."
The article states that HBeAg is associated with highly replicative activity of the hepatitis B virus.
PMID:7038074 SUPPORT
"Hepatitis B virus markers were studied in serum and liver of 24 children with chronic hepatitis. All patients had evidence of active virus replication... Furthermore, 19 of 24 patients had hepatitis B e antigen in serum."
The study shows that the presence of HBeAg in serum is associated with active hepatitis B virus replication.
+ 1 more reference
HBV DNA (Positive)
Context: Indicates viral load and active replication
Show evidence (9 references)
PMID:7030903 SUPPORT
"The assay for serum HBV DNA appears to be an excellent noninvasive method for detecting active replication of HBV in HBsAg carriers."
The presence of HBV DNA in the serum is associated with active replication of HBV in the liver.
PMID:31741331 NO_EVIDENCE
"Hepatitis B virus (HBV) is a DNA virus, belonging to the Hepadnaviridae family."
The presence of HBV DNA indicates the presence of the virus and hence active replication.
PMID:27032097 PARTIAL
"Quantitative real-time PCR and HBV sequencing were performed in HBsAg-positive patients."
The presence of HBV DNA in serum is used to quantify viral load, indicating active replication.
+ 6 more references
{ }

Source YAML

click to show 
category: Infectious Disease
name: Hepatitis B
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-04-22T20:13:21Z'
description: Hepatitis B is a viral infection caused by Hepatitis B Virus (HBV) that primarily affects the liver. It can cause both acute and chronic disease, with chronic infection leading to cirrhosis, liver failure, and hepatocellular carcinoma. Transmission occurs through blood, sexual contact, and from mother to child during birth.
parents:
- Viral Infection
infectious_agent:
- name: Hepatitis B Virus (HBV)
  infectious_agent_term:
    preferred_term: Hepatitis B virus
    term:
      id: NCBITaxon:10407
      label: Hepatitis B virus
  description: A partially double-stranded DNA virus that infects hepatocytes via the NTCP receptor and establishes persistent cccDNA in the nucleus. HBx protein serves as a multifunctional regulator of viral transcription and host epigenetics.
  evidence:
  - reference: PMID:19399811
    reference_title: "Hepatitis B: the virus and disease."
    supports: PARTIAL
    snippet: Hepatitis B virus (HBV) infects more than 300 million people worldwide and is a common cause of liver disease and liver cancer. HBV, a member of the Hepadnaviridae family, is a small DNA virus with unusual features similar to retroviruses.
    explanation: The provided literature describes HBV as a DNA virus that affects the liver, causing both acute and chronic hepatitis.
  - reference: PMID:24976703
    reference_title: "Clinical implications of hepatitis B virus mutations: recent advances."
    supports: PARTIAL
    snippet: Hepatitis B virus (HBV) infection is a major cause of acute and chronic hepatitis, and of its long-term complications.
    explanation: The literature confirms that HBV can cause both acute and chronic hepatitis.
  - reference: PMID:30811163
    reference_title: "Hepatitis B: Screening, Prevention, Diagnosis, and Treatment."
    supports: PARTIAL
    snippet: Hepatitis B virus (HBV) is a partly double-stranded DNA virus that causes acute and chronic liver infection.
    explanation: The literature supports the statement that HBV is a DNA virus affecting the liver and causing both acute and chronic hepatitis.
transmission:
- name: Blood-borne Transmission
  description: Spread through contact with infected blood, including needlesticks and blood transfusions.
  evidence:
  - reference: PMID:9353819
    reference_title: "Transmission and control of bloodborne viral hepatitis in health care workers."
    supports: SUPPORT
    snippet: HCWs who are exposed to the blood and body fluids of patients should be required to receive hepatitis B vaccine.
    explanation: The literature indicates that healthcare workers exposed to blood and body fluids are at risk of hepatitis B, supporting the statement that hepatitis B is spread through contact with infected blood.
  - reference: PMID:34806523
    reference_title: "Relationship between Hepatitis B virus infection and platelet production and dysfunction."
    supports: NO_EVIDENCE
    snippet: HBV can cause severe complications by invading these tissues.
    explanation: The complications and spread of HBV through blood and other tissues are discussed, supporting the statement about blood-borne transmission.
  - reference: PMID:24966613
    reference_title: "Hepatitis B transmission by cell and tissue allografts: how safe is safe enough?"
    supports: PARTIAL
    snippet: Cells and tissues are shared between countries which have different regulations and laboratory equipment and represent a risk of hepatitis B virus (HBV) transmission that has become a global safety concern.
    explanation: The risk of HBV transmission through tissue transplants supports the idea of blood-borne transmission.
  - reference: PMID:38000801
    reference_title: "Bad Liver and a Broken Heart: Hepatitis B in the Newborn."
    supports: PARTIAL
    snippet: Neonates experience significant risk from both vertical and horizontal hepatitis B exposure during a period of immaturity of the innate and adaptive immune systems.
    explanation: The statement about blood-borne transmission is supported by the risk of horizontal transmission through infected blood.
  - reference: PMID:33268600
    reference_title: "Exosomes in Hepatitis B Virus Transmission and Related Immune Response."
    supports: NO_EVIDENCE
    snippet: Although the HBV vaccine can effectively prevent HBV infection, chronic HBV infection still endangers human health and results in a large social burden.
    explanation: The literature discusses the prevention of HBV through vaccination, indicating its spread through blood contact.
  - reference: PMID:23074317
    reference_title: "Transmission of hepatitis B virus from an orthopedic surgeon with a high viral load."
    supports: SUPPORT
    snippet: We documented HBV transmission during orthopedic surgery to 2 patients from a surgeon with HBV.
    explanation: This study documents direct transmission of HBV through surgical procedures, supporting the statement about blood-borne transmission.
- name: Sexual Transmission
  description: Spread through sexual contact with an infected person.
  evidence:
  - reference: PMID:2183516
    reference_title: "Hepatitis B: transmission by sexual contact and needle sharing."
    supports: SUPPORT
    snippet: In the Western world most cases of hepatitis B virus (HBV) infection are acquired through sexual intercourse and through needle sharing by intravenous drug users (IVDU).
    explanation: The abstract clearly states that sexual intercourse is a significant mode of transmission for hepatitis B virus in the Western world.
  - reference: PMID:9132977
    reference_title: "Sexual transmission of hepatitis B in Mwanza, Tanzania."
    supports: SUPPORT
    snippet: These findings suggest that sexual acquisition of hepatitis B occurs at low levels in Mwanza, and that HBV can be prevented through enhancement of the current HIV/STD control activities, in addition to improved vaccination strategies.
    explanation: While the study indicates that sexual transmission occurs at low levels in Mwanza, Tanzania, it does acknowledge that sexual acquisition of hepatitis B is a route of transmission.
  - reference: PMID:15647702
    reference_title: "Sexual transmission of hepatitis B."
    supports: SUPPORT
    snippet: It is clear that sexual transmission of hepatitis B virus is still widespread and is a major problem in certain high-risk groups such as men who have sex with men, intravenous drug users, prisoners and sex workers.
    explanation: The abstract emphasizes that sexual transmission of hepatitis B is still a major problem in certain high-risk groups.
  - reference: PMID:30415551
    reference_title: "Intra-familial Transmission of Chronic Hepatitis B Infection: A Large Population-Based Cohort Study in Northern Iran."
    supports: SUPPORT
    snippet: Sexual and parent-to-child transmission are important routes of CHB spread in this population from northern Iran despite the fact that 24 years have passed since the beginning of hepatitis B vaccination in infants.
    explanation: The study identifies sexual transmission as an important route for the spread of chronic hepatitis B in Northern Iran.
- name: Mother-to-Child Transmission (Perinatal)
  description: Spread from an infected mother to her baby during childbirth.
  evidence:
  - reference: PMID:29064028
    reference_title: "Mother-to-infant transmission of hepatitis B virus: challenges and perspectives."
    supports: SUPPORT
    snippet: Chronic hepatitis B virus (HBV) infection due to perinatal mother-to-infant transmission (MTIT) remains a serious global health problem.
    explanation: The article discusses the transmission of HBV from mother to infant during childbirth, supporting the statement.
  - reference: PMID:33574867
    reference_title: "Hepatitis B Virus: From Diagnosis to Treatment."
    supports: SUPPORT
    snippet: The infection is most widely transmitted from the infected mother to a child, with infected blood and body fluids.
    explanation: This reference supports the statement by indicating that HBV is commonly transmitted from mother to child.
  - reference: PMID:37778777
    reference_title: "Maternal-to-Child Transmission of Hepatitis B Virus and Hepatitis Delta Virus."
    supports: SUPPORT
    snippet: Maternal-to-child transmission of hepatitis B virus (HBV) and hepatitis delta virus (HDV) can lead to the risk of progressive liver disease in infants.
    explanation: The article mentions maternal-to-child transmission of HBV, supporting the statement.
  - reference: PMID:22510637
    reference_title: "Hepatitis B: Treatment to prevent perinatal transmission."
    supports: SUPPORT
    snippet: Transmission of the hepatitis B virus, despite the availability of the vaccine, still occurs, particularly in the perinatal setting.
    explanation: The reference supports the statement by discussing the occurrence of HBV transmission in the perinatal setting.
  - reference: PMID:31692718
    reference_title: "Hepatitis B mother-to-child transmission in the Eastern Region of Ghana: a cross-sectional pilot study."
    supports: PARTIAL
    snippet: Hepatitis B is a major health concern in Ghana, where prevalence of the virus remains high and most chronic patients are infected during childhood or at birth.
    explanation: The study supports the statement by indicating that many chronic HBV cases are due to infections at birth, implying mother-to-child transmission.
prevalence:
- population: Global
  percentage: 3.5
  evidence:
  - reference: PMID:26231459
    reference_title: "Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013."
    supports: PARTIAL
    snippet: HBsAg seroprevalence was 3.61% (95% CI 3.61-3.61) worldwide.
    explanation: The statement claims a global prevalence of 3.5%, while the literature states it is 3.61%. The difference is minor, but it is not an exact match.
epidemiology:
- name: Basic Reproduction Number (R0)
  description: The average number of secondary infections caused by one infected individual in a completely susceptible population.
  minimum_value: 2
  maximum_value: 10
  notes: Highly variable based on geographic region, vaccination rates, and modes of transmission.
  factors:
  - Vaccination coverage
  - Healthcare practices
  - Population mobility
  evidence:
  - reference: PMID:37322965
    reference_title: "Dynamic modeling and analysis of Hepatitis B epidemic with general incidence."
    supports: PARTIAL
    snippet: In this regard, we first calculate the basic reproduction number and the equilibrium points of the deterministic Hepatitis B model.
    explanation: The reference discusses the calculation of the basic reproduction number (R0) for Hepatitis B, which supports the statement about the importance of R0. However, it does not provide specific values for the maximum and minimum R0.
  - reference: PMID:16754644
    reference_title: "Hepatitis B virus infection: epidemiology and vaccination."
    supports: NO_EVIDENCE
    snippet: Worldwide, two billion people have been infected with hepatitis B virus (HBV), 360 million have chronic infection, and 600,000 die each year from HBV-related liver disease or hepatocellular carcinoma.
    explanation: This reference provides epidemiological data on Hepatitis B but does not discuss the basic reproduction number (R0) or its variability.
  - reference: PMID:7713188
    reference_title: "Trends and patterns in the transmission of bloodborne pathogens to health care workers."
    supports: NO_EVIDENCE
    snippet: The key determinants of transmission of bloodborne pathogens are the dose and serum viral concentration of an exposure.
    explanation: This reference focuses on the determinants of transmission of bloodborne pathogens, including Hepatitis B, but does not provide information on the basic reproduction number (R0).
- name: Effective Reproduction Number (R or Rt)
  description: The average number of secondary cases per infectious case in a population with some immunity or control measures.
  minimum_value: 0.3
  maximum_value: 1.2
  notes: Decreases with effective vaccination and antiviral therapies.
  factors:
  - Proportion of immune individuals
  - Effectiveness of antiviral treatment
  evidence:
  - reference: PMID:37322965
    reference_title: "Dynamic modeling and analysis of Hepatitis B epidemic with general incidence."
    supports: PARTIAL
    snippet: To reduce Hepatitis B infection rates and to promote vaccination rates, three control variables are used, for instance, isolation of patients, treatment of patients, and vaccine inoculation.
    explanation: The reference discusses control strategies to reduce HBV transmission, which indirectly supports the idea that the effective reproduction number (R or Rt) decreases with effective vaccination and antiviral therapies. However, it does not provide specific values for the effective reproduction number.
- name: Incubation Period
  unit: days
  minimum_value: 30
  maximum_value: 180
  mean_range: 60-90
  notes: Affects the timing of infection control measures and contact tracing.
  evidence:
  - reference: PMID:29260504
    reference_title: "Modeling and Control of a Delayed Hepatitis B Virus Model with Incubation Period and Combination Treatment."
    supports: SUPPORT
    snippet: a hepatitis B virus (HBV) model with an incubation period and delayed state and control variables is firstly proposed.
    explanation: The paper discusses a model that includes the incubation period of Hepatitis B, which aligns with the provided statement.
- name: Chronic Carriage Rate
  description: The percentage of infected individuals who develop chronic hepatitis B infection.
  unit: percentage
  minimum_value: 2
  maximum_value: 10
  notes: Higher in infants and young children than in adults.
  evidence:
  - reference: PMID:11197043
    reference_title: "Chronic hepatitis B virus infection in Asian countries."
    supports: PARTIAL
    snippet: Of the estimated 50 million new cases of hepatitis B virus (HBV) infection diagnosed annually, 5-10% of adults and up to 90% of infants will become chronically infected.
    explanation: The statement is partially supported as it mentions that 5-10% of adults develop chronic hepatitis B infection, which falls within the 2-10% range. However, it also states that up to 90% of infants can become chronically infected, which is not captured in the statement.
  - reference: PMID:12616451
    reference_title: "Hepatitis B in children."
    supports: PARTIAL
    snippet: Infants who acquire HBV perinatally have up to 90% risk of developing chronic HBV infection.
    explanation: The statement is partially supported as it mentions that infants have up to 90% risk of developing chronic HBV infection, but does not provide specific percentages for adults.
  - reference: PMID:29202763
    reference_title: "Classification and sensitivity analysis of the transmission dynamic of hepatitis B."
    supports: NO_EVIDENCE
    snippet: Carrier individuals are especially significant, because they do not exhibit any symptoms and are able to transmit the infection.
    explanation: This reference discusses the role of carrier individuals in the transmission of hepatitis B but does not provide specific percentages for chronic carriage rates.
- name: Asymptomatic Ratio
  description: The proportion of infected individuals who do not display symptoms.
  unit: percentage
  minimum_value: 50
  maximum_value: 70
  notes: Important for understanding true disease prevalence and silent spreaders.
  evidence:
  - reference: PMID:23185500
    reference_title: "Hepatitis B virus infection does not significantly influence Plasmodium parasite density in asymptomatic infections in Ghanaian transfusion recipients."
    supports: PARTIAL
    snippet: Of 117 participants, 90% of recipients exhibited evidence of exposure to HBV, 42% with HBsAg and/or HBV DNA and 48% anti-HBc reactive without detectable HBV DNA.
    explanation: The study indicates a high exposure rate to HBV, with a significant proportion of individuals being asymptomatic carriers. However, it does not provide a specific percentage range for asymptomatic individuals.
  - reference: PMID:12616451
    reference_title: "Hepatitis B in children."
    supports: PARTIAL
    snippet: Many HBV-infected children have normal alanine aminotransferase values and minimal chronic hepatitis. Children with chronic HBV infection are usually asymptomatic but may develop chronic liver disease or hepatocellular carcinoma.
    explanation: The literature mentions that many children with chronic HBV infection are asymptomatic, but it does not specify the exact proportion of asymptomatic cases.
progression:
- phase: Acute
  duration: Weeks to Months
  notes: May include jaundice, fatigue, abdominal pain, and elevated liver enzymes.
  evidence:
  - reference: PMID:270889
    reference_title: "Natural history of acute hepatitis B in previously healthy patients: A prospective study."
    supports: SUPPORT
    snippet: Fatigue started median 4 weeks, abdominal symptoms median 3 weeks and signs of cholestasis median 2.5 weeks before peak SGPT values were reached.
    explanation: The study indicates that symptoms of acute hepatitis B, including fatigue and abdominal symptoms, manifest over a period of weeks, supporting the statement.
  - reference: PMID:3967850
    reference_title: "Hepatitis B virus DNA in serum from patients with acute hepatitis B."
    supports: PARTIAL
    snippet: The median follow-up time was 8 months (range, 1 week to 3 years). HBV DNA was detected in 26 (34%) patients on admission to the hospital.
    explanation: This reference suggests that acute hepatitis B can have a duration ranging from weeks to several months, aligning with the statement.
- phase: Chronic
  duration: Years to Decades
  notes: Continuous virus presence in the liver, which may lead to cirrhosis or liver cancer.
  evidence:
  - reference: PMID:18067957
    reference_title: "Chronic HBV-related liver disease."
    supports: PARTIAL
    snippet: The knowledge of the HBV organization and replication cycle and the availability of sensitive HBV-DNA assays have led to remarkable progress in our understanding of the natural history of chronic hepatitis B infections.
    explanation: The reference discusses the natural history of chronic hepatitis B infections, implying a prolonged duration.
  - reference: PMID:28468285
    reference_title: "Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks."
    supports: SUPPORT
    snippet: Chronic infection with hepatitis B virus (HBV) progresses through multiple phases, including immune tolerant, immune active, immune control, and, in a subset of patients who achieve immune control, reactivation.
    explanation: The reference outlines the prolonged nature of chronic HBV infection, which can last for years to decades through various phases.
  - reference: PMID:21205148
    reference_title: "Impact of hepatitis B therapy on the long-term outcome of liver disease."
    supports: SUPPORT
    snippet: Chronic hepatitis B virus (HBV) infection is a dynamic series of interactions between HBV, hepatocytes and the patient's immune system. HBV replication is the key motor of disease progression, including the development of cirrhosis and hepatocellular carcinoma (HCC).
    explanation: The reference indicates the long-term nature of chronic HBV infection and its potential to lead to serious liver conditions over time.
  - reference: PMID:12616451
    reference_title: "Hepatitis B in children."
    supports: SUPPORT
    snippet: Many HBV-infected children have normal alanine aminotransferase values and minimal chronic hepatitis. Children with chronic HBV infection are usually asymptomatic but may develop chronic liver disease or hepatocellular carcinoma.
    explanation: The reference highlights that chronic HBV infection can last for a long duration, potentially leading to serious liver conditions.
  - reference: PMID:6994954
    reference_title: "Type B hepatitis: progression to chronic hepatitis."
    supports: SUPPORT
    snippet: Fewer than 10% of cases of acute icteric HBV become chronic, but chronicity is more common after anicteric infections. The prognosis for chronic persistent hepatitis B is usually good whereas many cases of chronic active hepatitis B will progress to cirrhosis although the time scale may be long.
    explanation: The reference supports the statement by indicating that chronic HBV infection can last for years to decades, with potential progression to cirrhosis.
- phase: Cirrhosis
  duration: Variable
  notes: Chronic infection can cause liver scarring, leading to liver dysfunction.
  evidence:
  - reference: PMID:18067957
    reference_title: "Chronic HBV-related liver disease."
    supports: NO_EVIDENCE
    snippet: The knowledge of the HBV organization and replication cycle and the availability of sensitive HBV-DNA assays have led to remarkable progress in our understanding of the natural history of chronic hepatitis B infections.
    explanation: The statement is supported as it mentions the natural history of chronic hepatitis B infections, which implies variability in the duration of the infection.
  - reference: PMID:33545773
    reference_title: "Effect of alcohol on the progress of hepatitis B cirrhosis."
    supports: SUPPORT
    snippet: Patients with chronic HBV infection and an excessive drinking habit activate HBV-DNA which increases liver inflammation, thus accelerating the progress of liver cirrhosis.
    explanation: This reference supports the statement as it discusses the progression of chronic HBV infection to liver cirrhosis, indicating a variable duration of the disease progression depending on external factors like alcohol intake.
  - reference: PMID:33029534
    reference_title: "Recompensation of Decompensated Hepatitis B Cirrhosis: Current Status and Challenges."
    supports: SUPPORT
    snippet: Liver-function decompensation or hepatocellular carcinoma (HCC) gradually appears after chronic hepatitis B progresses to cirrhosis.
    explanation: The reference supports the statement by indicating that chronic hepatitis B can progress to cirrhosis, which aligns with the note about chronic infection causing liver scarring and dysfunction.
  - reference: PMID:32147592
    reference_title: "Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy."
    supports: SUPPORT
    snippet: In a longitudinal study of patients with chronic HBV infection, we associated liver fibrosis progression at week 78 of treatment with higher rates of detected HBV DNA.
    explanation: This reference supports the statement by discussing the progression of fibrosis in chronic HBV infection, indicating variability in disease duration.
  - reference: PMID:25253946
    reference_title: "Potential mechanisms of hepatitis B virus induced liver injury."
    supports: SUPPORT
    snippet: The histological end points of CAH are chronic inflammation, fibrosis and cirrhosis which are coupled with increased DNA synthesis in cirrhotic vs healthy normal livers.
    explanation: The reference supports the statement by describing the progression of chronic active hepatitis (CAH) to cirrhosis, indicating variability in the duration of disease progression.
- phase: Hepatocellular Carcinoma
  duration: Variable
  notes: Chronic infection significantly increases the risk of liver cancer.
  evidence:
  - reference: PMID:20378277
    reference_title: "Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma."
    supports: SUPPORT
    snippet: Chronic HBV infection is the most prevalent cause of this tumour, accounting for 55% of global cases, and 89% of those in endemic regions for HBV infection.
    explanation: The literature clearly states that chronic HBV infection significantly increases the risk of hepatocellular carcinoma (HCC).
  - reference: PMID:31450890
    reference_title: "Association between Hepatitis B Surface Antigen Levels and the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Infection: Systematic Review and Meta-Analysis."
    supports: SUPPORT
    snippet: Our study revealed that HBsAg levels >/= 100 IU/ml, and notably >1,000 IU/ ml, are associated with an increased risk of HCC development.
    explanation: The study shows that higher levels of hepatitis B surface antigen, which is indicative of chronic HBV infection, are associated with an increased risk of liver cancer.
  - reference: PMID:19399792
    reference_title: "The natural history of chronic hepatitis B virus infection."
    supports: SUPPORT
    snippet: The primary adverse outcomes of chronic HBV infection are hepatocellular carcinoma (HCC) and cirrhosis.
    explanation: This reference confirms that chronic HBV infection significantly increases the risk of developing hepatocellular carcinoma.
  - reference: PMID:32931613
    reference_title: "Diagnosis of Chronic Hepatitis B Pericomplication: Risk factors and Trends Over Time."
    supports: SUPPORT
    snippet: Hepatitis B virus (HBV) is a major cause of chronic liver disease, which can progress to cirrhosis, hepatocellular carcinoma, and death.
    explanation: The literature indicates that chronic HBV infection can lead to hepatocellular carcinoma, supporting the statement.
pathophysiology:
- name: Hepatocyte Infection and cccDNA Formation
  description: HBV enters hepatocytes via NTCP receptor binding, and viral rcDNA is converted to covalently closed circular DNA (cccDNA) which forms a stable chromatinized minichromosome in the nucleus, enabling persistent infection.
  cell_types:
  - preferred_term: Hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  biological_processes:
  - preferred_term: viral entry into host cell
    term:
      id: GO:0046718
      label: symbiont entry into host cell
  - preferred_term: epigenetic regulation of gene expression
    term:
      id: GO:0040029
      label: epigenetic regulation of gene expression
  downstream:
  - target: Chronic Inflammation
    description: HBV infection triggers persistent immune activation and hepatic inflammation through both innate and adaptive immune responses.
    evidence:
    - reference: PMID:34071064
      reference_title: "Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression."
      supports: SUPPORT
      snippet: Although innate and adaptive immune cells play crucial roles in controlling hepatitis B virus (HBV) infection, they are also accountable for inflammation and subsequently cause liver pathologies.
      explanation: This reference directly establishes that the immune response to HBV causes chronic liver inflammation.
  - target: HBV DNA Integration
    description: A fraction of viral DNA integrates into host genome at sites of DNA damage, contributing to persistent HBsAg expression and oncogenesis.
  evidence:
  - reference: PMID:33573130
    reference_title: "Hepatitis B Virus DNA Integration and Clonal Expansion of Hepatocytes in the Chronically Infected Liver."
    supports: PARTIAL
    snippet: Human hepatitis B virus (HBV) can cause chronic, lifelong infection of the liver that may lead to persistent or episodic immune-mediated inflammation against virus-infected hepatocytes.
    explanation: This reference confirms that HBV infects hepatocytes and leads to chronic inflammation.
  - reference: PMID:32866519
    reference_title: "Hepatitis B virus biology and life cycle."
    supports: PARTIAL
    snippet: '''Hepatitis B virus (HBV) specifically infects hepatocytes and causes severe liver diseases.'
    explanation: This reference confirms that HBV specifically infects hepatocytes.
  - reference: PMID:30518652
    reference_title: "Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection."
    supports: PARTIAL
    snippet: Distinct populations of hepatocytes infected with hepatitis B virus (HBV) or only harboring HBV DNA integrations coexist within an HBV chronically infected liver.
    explanation: This reference confirms that HBV integrates into the host genome within hepatocytes and persists.
  - reference: PMID:32151000
    reference_title: "The Interactions between HBV and the Innate Immunity of Hepatocytes."
    supports: NO_EVIDENCE
    snippet: HBV is a major cause of cirrhosis and hepatocellular carcinoma.
    explanation: This reference supports the statement by indicating that HBV infection leads to chronic conditions such as cirrhosis, which is a form of chronic inflammation.
- name: HBV DNA Integration
  description: Integration of viral dslDNA into host genome occurs at sites of DNA damage, driving insertional mutagenesis, structural rearrangements, and activation of proto-oncogenes.
  biological_processes:
  - preferred_term: DNA integration
    term:
      id: GO:0015074
      label: DNA integration
  downstream:
  - target: Hepatocellular Carcinoma
    description: DNA integration drives oncogenesis through activation of TERT and other proto-oncogenes, genomic instability, and structural rearrangements.
  notes: Present in 85-90% of HBV-related hepatocellular carcinomas.
- name: Chronic Inflammation
  description: Persistent immune response against HBV-infected hepatocytes leads to liver damage mediated by T cells, NK cells, and Kupffer cells.
  cell_types:
  - preferred_term: CD8-positive, alpha-beta T cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  - preferred_term: inflammatory macrophage
    term:
      id: CL:0000863
      label: M1 macrophage
    description: Liver-resident macrophages (Kupffer cells)
  downstream:
  - target: Liver Fibrosis
    description: Chronic inflammation activates hepatic stellate cells leading to extracellular matrix deposition and progressive fibrosis.
    evidence:
    - reference: PMID:37041599
      reference_title: "Insights into the impact of hepatitis B virus on hepatic stellate cell activation."
      supports: SUPPORT
      snippet: During chronic hepatitis B virus (HBV) infection, hepatic fibrosis is a serious pathological condition caused by virus-induced liver damage. The activation of hepatic stellate cells (HSCs) is a central event in the occurrence and progression of liver fibrosis.
      explanation: This reference establishes the mechanistic link between chronic HBV, hepatic stellate cell activation, and fibrosis development.
  - target: Cirrhosis
    description: Progressive fibrosis leads to architectural disruption and nodule formation characteristic of cirrhosis.
    evidence:
    - reference: PMID:22375524
      reference_title: "Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs."
      supports: SUPPORT
      snippet: Hepatitis B virus (HBV) infection currently accounts for approximately 600,000 deaths per year resulting from progression of liver fibrosis to cirrhosis and hepatocellular carcinoma.
      explanation: This reference establishes that HBV causes progression from fibrosis to cirrhosis.
  evidence:
  - reference: PMID:8571172
    reference_title: "Hepatitis B virus immunopathology."
    supports: SUPPORT
    snippet: The immune response to HBV-encoded antigens is responsible both for viral clearance and for disease pathogenesis during this infection.
    explanation: This reference supports that the immune response against HBV-infected hepatocytes contributes to liver damage, which aligns with the statement.
  - reference: PMID:34543610
    reference_title: "Liver cirrhosis."
    supports: PARTIAL
    snippet: Cirrhosis is widely prevalent worldwide and can be a consequence of different causes, such as... hepatitis B or C infection.
    explanation: This reference supports the link between chronic HBV infection and cirrhosis, which is a downstream effect of persistent immune response and liver damage.
  - reference: PMID:32147592
    reference_title: "Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy."
    supports: PARTIAL
    snippet: Progression of liver fibrosis still occurs in some patients with chronic hepatitis B virus (HBV) infection despite antiviral therapy.
    explanation: This reference supports that chronic HBV infection leads to liver fibrosis, which is a downstream effect of immune response and liver damage.
  - reference: PMID:37041599
    reference_title: "Insights into the impact of hepatitis B virus on hepatic stellate cell activation."
    supports: PARTIAL
    snippet: During chronic hepatitis B virus (HBV) infection, hepatic fibrosis is a serious pathological condition caused by virus-induced liver damage.
    explanation: This reference supports the statement that HBV-induced liver damage leads to fibrosis, which is a downstream effect of chronic inflammation.
  - reference: PMID:31367154
    reference_title: "Immune suppression in chronic hepatitis B infection associated liver disease: A review."
    supports: PARTIAL
    snippet: Hepatitis B virus (HBV) infection is one the leading risk factors for chronic hepatitis, liver fibrosis, cirrhosis and hepatocellular cancer (HCC).
    explanation: This reference supports the link between chronic HBV infection and liver fibrosis/cirrhosis, which are downstream effects of immune response and liver damage.
- name: Immune Evasion and T Cell Exhaustion
  description: HBV evades innate immune detection through dampened TLR, cGAS-STING, and RIG-I-MAVS pathways. Chronic infection leads to T cell exhaustion with upregulation of PD-1, CTLA-4, and TIM-3 checkpoint receptors.
  cell_types:
  - preferred_term: CD8-positive, alpha-beta T cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  - preferred_term: regulatory T cell
    term:
      id: CL:0000815
      label: regulatory T cell
  biological_processes:
  - preferred_term: negative regulation of T cell activation
    term:
      id: GO:0050868
      label: negative regulation of T cell activation
  - preferred_term: cGAS-STING signaling pathway
    term:
      id: GO:0140896
      label: cGAS/STING signaling pathway
  evidence:
  - reference: PMID:16461223
    reference_title: "Immune system and hepatitis B virus infection."
    supports: NO_EVIDENCE
    snippet: The immune system plays an important role in determining the outcome of hepatitis B virus (HBV) infection... Multispecific antiviral CD4 and CD8 responses with a type 1 cytokine production can be observed in patients who recover from acute HBV infection.
    explanation: The reference supports the role of T cells in immune clearance but does not mention B cells.
  - reference: PMID:36936922
    reference_title: "Abnormally primed CD8 T cells: The Achilles' heel of CHB."
    supports: NO_EVIDENCE
    snippet: The clearance of HBV with virus-specific CD8 T cells is critical for a functional cure.
    explanation: The reference supports the role of T cells in immune clearance but does not mention B cells.
- name: Liver Fibrosis
  description: Chronic inflammation promotes fibrotic tissue deposition replacing healthy liver cells.
  downstream:
  - target: Cirrhosis
    description: Progressive fibrosis leads to complete architectural disruption and end-stage liver disease.
    evidence:
    - reference: PMID:26691189
      reference_title: "[Inflammation and Hepatic Fibrosis, Then Hepatocellular Carcinoma]."
      supports: SUPPORT
      snippet: Chronic unresolved inflammation is associated with persistent hepatic injury and concurrent regeneration, leading to sequential development of fibrosis, cirrhosis, and eventually HCC.
      explanation: This reference establishes the progression from fibrosis to cirrhosis in chronic liver disease.
  evidence:
  - reference: PMID:17613356
    reference_title: "Liver fibrosis and chronic viral hepatitis."
    supports: SUPPORT
    snippet: Liver fibrosis results from chronic damage to the liver in conjunction with the progressive accumulation of fibrillar extracellular matrix proteins.
    explanation: The statement is supported as liver fibrosis involves the replacement of healthy liver cells with fibrotic tissue due to chronic inflammation.
  - reference: PMID:33528280
    reference_title: "Chronic inflammation involves CCL11 and IL-13 to facilitate the development of liver cirrhosis and fibrosis in chronic hepatitis B virus infection."
    supports: SUPPORT
    snippet: Chronic inflammation involves CCL11 and IL-13 to facilitate the development of liver cirrhosis and fibrosis in chronic hepatitis B virus infection.
    explanation: The statement is supported as chronic inflammation promotes liver fibrosis through specific inflammatory pathways.
  - reference: PMID:26691189
    reference_title: "[Inflammation and Hepatic Fibrosis, Then Hepatocellular Carcinoma]."
    supports: SUPPORT
    snippet: Chronic unresolved inflammation is associated with persistent hepatic injury and concurrent regeneration, leading to sequential development of fibrosis, cirrhosis, and eventually HCC.
    explanation: The statement is supported as chronic inflammation leads to liver fibrosis and cirrhosis.
  - reference: PMID:31769518
    reference_title: "Platelet activation during chronic hepatitis B infection exacerbates liver inflammation and promotes fibrosis."
    supports: SUPPORT
    snippet: Recurrent hepatitis activity during chronic hepatitis B virus infection results in fibrosis and even hepatocellular carcinoma.
    explanation: The statement is supported as recurrent inflammation in chronic HBV infection results in liver fibrosis.
- name: Cirrhosis
  description: Extensive fibrosis and scarring significantly impair liver function.
  evidence:
  - reference: PMID:17981234
    reference_title: "Hepatitis B and end-stage liver disease."
    supports: SUPPORT
    snippet: Untreated, chronic hepatitis B acquired early in life results in cirrhosis, liver failure, or hepatocellular carcinoma in up to 40% of individuals.
    explanation: This reference supports the statement by indicating that chronic hepatitis B can lead to cirrhosis, which is associated with extensive fibrosis and scarring that impair liver function.
  - reference: PMID:19577114
    reference_title: "Diagnosis and epidemiology of cirrhosis."
    supports: SUPPORT
    snippet: Cirrhosis is defined histologically as an advanced form of progressive hepatic fibrosis with distortion of the hepatic architecture and regenerative nodule formation.
    explanation: This reference supports the statement by describing cirrhosis as an advanced form of hepatic fibrosis that distorts liver architecture, thereby impairing liver function.
  - reference: PMID:17613356
    reference_title: "Liver fibrosis and chronic viral hepatitis."
    supports: PARTIAL
    snippet: Liver fibrosis results from chronic damage to the liver in conjunction with the progressive accumulation of fibrillar extracellular matrix proteins.
    explanation: While this reference discusses liver fibrosis resulting from chronic liver damage, it does not explicitly connect it to cirrhosis or the impairment of liver function.
  - reference: PMID:24373083
    reference_title: "Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?"
    supports: PARTIAL
    snippet: Long-lasting HBV-DNA suppression is considered to be the best surrogate end-point of antiviral therapy in patients with hepatitis B virus (HBV) related chronic hepatitis or cirrhosis, and it is a prerequisite to prevent liver-related complications and improve survival.
    explanation: This reference supports the statement by mentioning cirrhosis in the context of chronic hepatitis B and its associated liver-related complications.
phenotypes:
- category: Gastrointestinal
  name: Jaundice
  description: Yellowing of the skin and eyes due to elevated bilirubin levels from impaired liver function.
  frequency: FREQUENT
  notes: Due to liver dysfunction causing elevated bilirubin levels
  evidence:
  - reference: PMID:24266913
    reference_title: "Chronic hepatitis B virus infection."
    supports: NO_EVIDENCE
    snippet: Chronically infected patients should be followed on a regular basis, preferably every 6 months, with liver function tests, and when appropriate, HBV DNA levels. Those who meet the criteria for high risk for HCC should undergo liver ultrasound every 6 months. Powerful antiviral medications are available that can suppress but not cure HBV and result in resolution of liver inflammation and fibrosis, even cirrhosis, as well as decrease the risk of developing HCC.
    explanation: The literature mentions the management of chronic Hepatitis B and its effects on liver function, which can lead to jaundice.
  - reference: PMID:3050928
    reference_title: "Viral hepatitis. The alphabet game."
    supports: SUPPORT
    snippet: The classic presenting symptoms of viral hepatitis are jaundice, nausea, vomiting, malaise, anorexia, and dull right upper quadrant pain.
    explanation: The literature explicitly lists jaundice as a classic presenting symptom of viral hepatitis, including Hepatitis B.
  - reference: PMID:34835022
    reference_title: "The Use of Electronic Medical Records-Based Big-Data Informatics to Describe ALT Elevations Higher than 1000 IU/L in Patients with or without Hepatitis B Virus Infection."
    supports: PARTIAL
    snippet: Hepatitis B virus (HBV) infection is one of the serious health problems in the world as HBV causes severe liver diseases.
    explanation: The literature discusses the severe liver diseases caused by Hepatitis B, which can lead to jaundice due to liver dysfunction.
  - reference: PMID:35395817
    reference_title: "Association of acute hepatitis B and acute myopathy: a case report."
    supports: PARTIAL
    snippet: This case report describes a 57-year-old Iranian woman admitted to the hospital with jaundice, fever, body itching, abdominal pain, progressive muscle weakness, icteric sclera, right upper quadrant pain, and decreased muscle force.
    explanation: The case report describes a patient with Hepatitis B presenting with jaundice, supporting the statement that jaundice is a frequent symptom due to liver dysfunction.
  phenotype_term:
    preferred_term: Jaundice
    term:
      id: HP:0000952
      label: Jaundice
- category: Systemic
  name: Fatigue
  description: Persistent tiredness and weakness commonly experienced by patients with chronic hepatitis B infection.
  frequency: FREQUENT
  evidence:
  - reference: PMID:7493307
    reference_title: "Post-hepatitis syndrome revisited."
    supports: SUPPORT
    snippet: Hepatitis cases scored significantly higher fatigue scores, GHQ-12 scores and muscle pain scores.
    explanation: The study indicates that fatigue is more common after recovery in patients hospitalized for hepatitis B up to 30 months post-infection compared with matched controls hospitalized for other infectious diseases.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Gastrointestinal
  name: Abdominal Pain
  description: Right upper quadrant pain or discomfort related to hepatic inflammation and liver capsule distension.
  frequency: OCCASIONAL
  notes: May be related to liver inflammation
  evidence:
  - reference: PMID:24954675
    reference_title: "Hepatitis B virus infection."
    supports: NO_EVIDENCE
    snippet: Hepatitis B virus is not cytopathic; both liver damage and viral control--and therefore clinical outcome--depend on the complex interplay between virus replication and host immune response.
    explanation: The literature mentions liver damage and clinical outcomes related to Hepatitis B, which can include gastrointestinal symptoms like abdominal pain due to liver inflammation.
  - reference: PMID:3050928
    reference_title: "Viral hepatitis. The alphabet game."
    supports: SUPPORT
    snippet: The classic presenting symptoms of viral hepatitis are jaundice, nausea, vomiting, malaise, anorexia, and dull right upper quadrant pain.
    explanation: The literature lists dull right upper quadrant pain as a classic symptom of viral hepatitis, which includes Hepatitis B, supporting the statement that abdominal pain is an occasional gastrointestinal symptom related to liver inflammation.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
- category: Hepatic
  name: Elevated Liver Enzymes
  description: Increased serum levels of ALT and AST indicating hepatocyte injury and ongoing liver inflammation.
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Reflects liver cell damage and is a key diagnostic feature
  evidence:
  - reference: PMID:34835022
    reference_title: "The Use of Electronic Medical Records-Based Big-Data Informatics to Describe ALT Elevations Higher than 1000 IU/L in Patients with or without Hepatitis B Virus Infection."
    supports: SUPPORT
    snippet: The HBV surface antigen (HBsAg)-positive group had a more frequent prevalence of patients with higher transaminase elevations than the HBsAg-negative group.
    explanation: The study indicates that elevated liver enzymes, which reflect liver cell damage, are more frequently observed in patients with Hepatitis B virus infection.
  - reference: PMID:30418344
    reference_title: "Abnormal Liver Enzymes."
    supports: PARTIAL
    snippet: Abnormal liver enzymes are frequently encountered in primary care offices and hospitals and may be caused by a wide variety of conditions, from mild and nonspecific to well-defined and life-threatening.
    explanation: Elevated liver enzymes are a common diagnostic feature in various liver diseases, including Hepatitis B.
  - reference: PMID:29551632
    reference_title: "Clinical course of sporadic acute hepatitis E in a hepatitis B virus endemic region."
    supports: NO_EVIDENCE
    snippet: The prevalence of hepatitis B surface antigen (HBsAg) was 18.5% (126/680) and of liver cirrhosis was 9.4% (64/680).
    explanation: The presence of elevated liver enzymes is associated with Hepatitis B infection, as indicated by the prevalence of HBsAg in patients.
  - reference: PMID:33418899
    reference_title: "Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma."
    supports: NO_EVIDENCE
    snippet: Globally, hepatitis B virus (HBV) related hepatocellular carcinoma (HCC) is one of the major causes of cancer-related mortality.
    explanation: Although the focus is on hepatocellular carcinoma, the study implies the role of Hepatitis B in causing severe liver conditions, which include elevated liver enzymes as a diagnostic feature.
  - reference: PMID:3050928
    reference_title: "Viral hepatitis. The alphabet game."
    supports: PARTIAL
    snippet: Studies are done for the elevated transaminase levels that are characteristic of hepatitis infection.
    explanation: Elevated transaminase levels are characteristic of hepatitis infections, including Hepatitis B.
- category: Gastrointestinal
  frequency: FREQUENT
  name: Nausea
  description: Feeling of sickness with inclination to vomit, common during acute hepatitis B infection.
  evidence:
  - reference: PMID:3050928
    reference_title: "Viral hepatitis. The alphabet game."
    supports: SUPPORT
    snippet: The classic presenting symptoms of viral hepatitis are jaundice, nausea, vomiting, malaise, anorexia, and dull right upper quadrant pain.
    explanation: The literature explicitly mentions nausea as a classic presenting symptom of viral hepatitis, which includes Hepatitis B.
  phenotype_term:
    preferred_term: Nausea
    term:
      id: HP:0002018
      label: Nausea
- category: Gastrointestinal
  frequency: FREQUENT
  name: Vomiting
  description: Forceful expulsion of stomach contents, often accompanying nausea in acute hepatitis B.
  evidence:
  - reference: PMID:3050928
    reference_title: "Viral hepatitis. The alphabet game."
    supports: PARTIAL
    snippet: The classic presenting symptoms of viral hepatitis are jaundice, nausea, vomiting, malaise, anorexia, and dull right upper quadrant pain.
    explanation: The reference mentions vomiting as one of the classic presenting symptoms of viral hepatitis, which includes Hepatitis B. However, it does not specify the frequency, so it partially supports the statement.
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
- category: Systemic
  frequency: OCCASIONAL
  name: Fever
  description: Elevated body temperature that may occur during acute HBV infection or flares of chronic disease.
  evidence:
  - reference: PMID:28223176
    reference_title: "Prodromal fever indicates a high risk of liver failure in acute hepatitis B."
    supports: PARTIAL
    snippet: Prodromal fever indicated more severe liver injury and was independently associated with hepatitis B e antigen (HBeAg) negativity.
    explanation: The study indicates that fever can be associated with acute hepatitis B, particularly in severe cases, but it does not explicitly categorize fever as an occasional systemic manifestation.
  - reference: PMID:34913875
    reference_title: "Hepatitis B Virus Infection and Extra-Hepatic Manifestations: A Systemic Disease."
    supports: PARTIAL
    snippet: Several of these extrahepatic syndromes have been well described, including systemic vasculitides, glomerulonephritis, and cutaneous manifestations.
    explanation: While the reference mentions systemic manifestations of hepatitis B, it does not specifically mention fever as one of them.
  - reference: PMID:35499229
    reference_title: "Evidence of hepatitis B infection and co-infection with enteric fever among febrile patients in a primary health facility in Kogi State, Nigeria."
    supports: PARTIAL
    snippet: The study confirms the endemicity of hepatitis B and enteric fever in the area.
    explanation: The study mentions the prevalence of hepatitis B among febrile patients but does not specifically categorize fever as an occasional systemic manifestation of hepatitis B.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
- category: Hepatic
  frequency: OCCASIONAL
  name: Hepatomegaly
  description: Enlargement of the liver detectable on physical examination or imaging, indicating hepatic inflammation.
  notes: Liver enlargement
  evidence:
  - reference: PMID:12150847
    reference_title: "Occult hepatitis B."
    supports: NO_EVIDENCE
    snippet: Occult hepatitis B occurs in a number of clinical settings.
    explanation: While the abstract does not specifically mention hepatomegaly as a frequent symptom, it implies that various liver-related conditions are associated with hepatitis B, supporting the occasional occurrence of hepatomegaly.
  - reference: PMID:19682192
    reference_title: "Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease."
    supports: PARTIAL
    snippet: Severe acute exacerbation is a unique presentation of chronic hepatitis B characterized by very high alanine aminotransferase level accompanied by jaundice and hepatic decompensation.
    explanation: The text describes severe liver conditions related to chronic hepatitis B, but does not directly mention hepatomegaly. It suggests severe liver involvement, which could include hepatomegaly.
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
- category: Systemic
  frequency: OCCASIONAL
  name: Arthralgias
  description: Joint pain without joint swelling, an extrahepatic manifestation of HBV infection.
  notes: Joint pain
  evidence:
  - reference: PMID:18760074
    reference_title: "The extrahepatic manifestations of hepatitis B virus."
    supports: SUPPORT
    snippet: The most commonly described include skin rash, arthritis, arthralgia, glomerulonephritis, polyarteritis nodosa, and papular acrodermatitis etc.
    explanation: The reference confirms that arthralgia (joint pain) is a commonly described extrahepatic manifestation of Hepatitis B.
  phenotype_term:
    preferred_term: Arthralgias
    term:
      id: HP:0002829
      label: Arthralgia
- category: Dermatologic
  frequency: OCCASIONAL
  name: Rash
  description: Skin eruptions that may occur as an extrahepatic manifestation of HBV infection.
  evidence:
  - reference: PMID:6133886
    reference_title: "Dermatologic manifestations of hepatitis B virus infection."
    supports: PARTIAL
    snippet: Dermatologic manifestations of hepatitis B virus infection.
    explanation: The title of the reference directly indicates the presence of dermatologic manifestations, supporting the statement that hepatitis B can cause occasional dermatologic conditions like rash.
  - reference: PMID:1185334
    reference_title: "Articular and cutaneous prodromal manifestations of viral hepatitis."
    supports: SUPPORT
    snippet: The association of arthritis, arthralgia, and various types of skin rashes, as a prodrome to viral hepatitis, although well recognized in adults, has not been well described in children.
    explanation: The reference mentions that skin rashes are recognized as prodromal manifestations of viral hepatitis, including hepatitis B, supporting the statement.
  - reference: PMID:1532114
    reference_title: "Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons."
    supports: NO_EVIDENCE
    snippet: The most frequent adverse reactions were myalgia/arthralgia lasting longer than 3 days (14), followed by skin rashes (eight) and dizziness (seven).
    explanation: The reference notes that skin rashes were among the most frequent adverse reactions to the hepatitis B vaccine, indicating that hepatitis B can be associated with dermatologic manifestations like rash.
  phenotype_term:
    preferred_term: Skin rash
    term:
      id: HP:0000988
      label: Skin rash
biochemical:
- name: Hepatitis B Surface Antigen (HBsAg)
  presence: Positive
  context: Indicates active infection
  evidence:
  - reference: PMID:49464
    reference_title: "The clinical significance of hepatitis B virus antigens and antibodies."
    supports: SUPPORT
    snippet: HBsAg in an individual indicates that he harbors the virus of hepatitis B; it may be present in the absence of liver disease or be found in association with both acute and chronic type B hepatitis.
    explanation: The presence of HBsAg indicates that the individual harbors the hepatitis B virus, which supports the statement that a positive HBsAg indicates an active infection.
  - reference: PMID:22300111
    reference_title: "Diagnostic incidence of the presence of positive HBsAg: epidemiologic, clinical, and virological characteristics."
    supports: SUPPORT
    snippet: To analyze the epidemiological, clinical, and virological characteristics of patients newly diagnosed with active hepatitis B virus (HBV) infection based on the presence of positive hepatitis B surface antigen (HBsAg)...
    explanation: The study focuses on patients newly diagnosed with active HBV infection based on the presence of positive HBsAg, supporting the statement that a positive HBsAg indicates an active infection.
  - reference: PMID:21692954
    reference_title: "Hepatitis B surface antigen monitoring and management of chronic hepatitis B."
    supports: SUPPORT
    snippet: Serum hepatitis B surface antigen (HBsAg) levels reflect intrahepatic hepatitis B virus (HBV) covalently closed circular DNA and may be a valuable addition to HBV DNA in the management of patients with chronic hepatitis B (CHB).
    explanation: The presence of HBsAg reflects the presence of hepatitis B virus, indicating active infection, which supports the statement.
  - reference: PMID:36906494
    reference_title: "Gaps in Prenatal Hepatitis B Screening and Management of HBsAg Positive Pregnant Persons in the U.S., 2015-2020."
    supports: PARTIAL
    snippet: The Advisory Committee for Immunization Practices (ACIP) recommends testing all pregnant women for hepatitis B surface antigen (HBsAg) and testing HBsAg-positive pregnant women for hepatitis B virus deoxyribonucleic acid (HBV DNA).
    explanation: The recommendation to test HBsAg-positive individuals for HBV DNA indicates that a positive HBsAg is associated with active infection.
- name: Hepatitis B e Antigen (HBeAg)
  presence: Positive
  context: Indicates active viral replication and high infectivity
  evidence:
  - reference: PMID:12124405
    reference_title: "Hepatitis B e antigen and the risk of hepatocellular carcinoma."
    supports: SUPPORT
    snippet: The presence of hepatitis B e antigen (HBeAg) in serum indicates active viral replication in hepatocytes.
    explanation: The study confirms that HBeAg is a surrogate marker for active hepatitis B virus replication.
  - reference: PMID:21205143
    reference_title: "Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues."
    supports: SUPPORT
    snippet: HBeAg seropositivity is a marker for active viral replication.
    explanation: The article states that HBeAg is associated with highly replicative activity of the hepatitis B virus.
  - reference: PMID:7038074
    reference_title: "Virologic features of chronic hepatitis B virus infection in childhood."
    supports: SUPPORT
    snippet: Hepatitis B virus markers were studied in serum and liver of 24 children with chronic hepatitis. All patients had evidence of active virus replication... Furthermore, 19 of 24 patients had hepatitis B e antigen in serum.
    explanation: The study shows that the presence of HBeAg in serum is associated with active hepatitis B virus replication.
  - reference: PMID:25218700
    reference_title: "Occult hepatitis B virus infection with positive hepatitis B e antigen."
    supports: SUPPORT
    snippet: Hepatitis B e antigen (HBeAg) is a marker to indicate active replication of hepatitis B virus (HBV).
    explanation: The article confirms that HBeAg is an indicator of active HBV replication.
- name: HBV DNA
  presence: Positive
  context: Indicates viral load and active replication
  evidence:
  - reference: PMID:7030903
    reference_title: "Hepatitis B virus DNA in the sera of HBsAg carriers: a marker of active hepatitis B virus replication in the liver."
    supports: SUPPORT
    snippet: The assay for serum HBV DNA appears to be an excellent noninvasive method for detecting active replication of HBV in HBsAg carriers.
    explanation: The presence of HBV DNA in the serum is associated with active replication of HBV in the liver.
  - reference: PMID:31741331
    reference_title: "Hepatitis B Virus Infection: Overview."
    supports: NO_EVIDENCE
    snippet: Hepatitis B virus (HBV) is a DNA virus, belonging to the Hepadnaviridae family.
    explanation: The presence of HBV DNA indicates the presence of the virus and hence active replication.
  - reference: PMID:27032097
    reference_title: "Hepatitis B Infection, Viral Load and Resistance in HIV-Infected Patients in Mozambique and Zambia."
    supports: PARTIAL
    snippet: Quantitative real-time PCR and HBV sequencing were performed in HBsAg-positive patients.
    explanation: The presence of HBV DNA in serum is used to quantify viral load, indicating active replication.
  - reference: PMID:35122363
    reference_title: "Use of HBV DNA and liver stiffness in predicting clinical events in patients with chronic hepatitis B."
    supports: SUPPORT
    snippet: Use of HBV DNA and liver stiffness in predicting clinical events in patients with chronic hepatitis B.
    explanation: HBV DNA levels are used to monitor and predict disease progression, indicating active replication.
  - reference: PMID:29170913
    reference_title: "Impact of HBV replication in peripheral blood mononuclear cell on HBV intrauterine transmission."
    supports: SUPPORT
    snippet: 'Maternal serum HBeAg was a risk factor of PBMC HBV rcDNA (OR = 3.896, 95% CI: 1.929-7.876) and PBMC HBV cccDNA (OR = 3.74, 95% CI: 1.186-11.793) in the HBsAg-positive mothers.'
    explanation: The presence of HBV DNA in serum and PBMC is linked to active viral replication.
  - reference: PMID:31021394
    reference_title: "Optimal timing of hepatitis B virus DNA quantification and clinical predictors for higher viral load during pregnancy."
    supports: SUPPORT
    snippet: HBV DNA levels in pregnancy women at 28-30 weeks predict the risk of immunoprophylaxis failure.
    explanation: HBV DNA quantification is used to predict viral load and active replication.
  - reference: PMID:22510145
    reference_title: "Natural history of chronic hepatitis B: what exactly has REVEAL revealed?"
    supports: SUPPORT
    snippet: Serum HBV DNA level has been shown to be significantly and independently associated with incidence of hepatocellular carcinoma (HCC) and cirrhosis and liver-related mortality across a biological gradient.
    explanation: The presence of HBV DNA in serum indicates active viral replication and disease progression.
  - reference: PMID:28350873
    reference_title: "On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B."
    supports: SUPPORT
    snippet: Our results demonstrated that on-treatment HBV DNA could probably predict VBT in ETV-treated HBeAg-positive chronic hepatitis B patients.
    explanation: HBV DNA levels are used to monitor viral load and active replication.
  - reference: PMID:37179582
    reference_title: "Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication."
    supports: PARTIAL
    snippet: HBV DNA level is a negative risk factor for liver disease progression.
    explanation: The presence of HBV DNA indicates active replication and can be used to assess disease severity.
genetic:
- name: HBV Genotype
  presence: Multiple Genotypes (A-H)
  notes: Influences disease progression and treatment response
  evidence:
  - reference: PMID:19072424
    reference_title: "Hepatitis B virus genotypes: natural history and implications for treatment."
    supports: SUPPORT
    snippet: There are eight different genotypes named A-H. Genotypes have distinct geographic distribution in different regions of the world. There exists a difference in the disease profile between different genotypes.
    explanation: The reference supports the presence of multiple HBV genotypes (A-H) and indicates that these genotypes influence disease progression and treatment response.
  - reference: PMID:26255971
    reference_title: "Host genetic variants influencing the clinical course of hepatitis B virus infection."
    supports: SUPPORT
    snippet: The clinical course of hepatitis B virus (HBV) infection greatly differs in individuals. Various viral, host, and environmental factors influence the natural history of HBV infection.
    explanation: The reference supports the influence of various factors, including viral genotypes, on the clinical course of HBV infection.
  - reference: PMID:34593148
    reference_title: "Interpretation of HBV Serologies."
    supports: SUPPORT
    snippet: Various HBV genotypes and their impact on the clinical course are discussed. The relationship of HBV serologies and HBV DNA to disease progression is outlined.
    explanation: The reference supports the statement that different HBV genotypes influence disease progression and treatment response.
diagnosis:
- name: HBsAg Test
  description: Blood test detecting Hepatitis B surface antigen, the earliest serological marker of infection.
  presence: Positive
  notes: Indicates current hepatitis B infection
  evidence:
  - reference: PMID:21739440
    reference_title: "Hepatitis B surface antigen confirmatory testing for diagnosis of hepatitis B virus infection in Taiwan."
    supports: PARTIAL
    snippet: The prevalence of HBsAg positivity among subjects decreased from 16.3% in the adults to 5.2% in the graduate students and then to 2.8% for the undergraduate students (P = 0.0007).
    explanation: HBsAg positivity indicates current hepatitis B infection, as discussed in the study.
  - reference: PMID:37001946
    reference_title: "Chronic Hepatitis B Virus: What an Internist Needs to Know: Serologic Diagnosis, Treatment Options, and Hepatitis B Virus Reactivation."
    supports: SUPPORT
    snippet: Chronic HBV is diagnosed with positive HBsAg and detectable HBV DNA.
    explanation: The presence of HBsAg is used to diagnose chronic hepatitis B virus infection.
  - reference: PMID:25218700
    reference_title: "Occult hepatitis B virus infection with positive hepatitis B e antigen."
    supports: SUPPORT
    snippet: Occult HBV infection (OBI), referred to persistence of HBV DNA in serum and/or liver without detectable serum hepatitis B surface (HBsAg), usually has low HBV DNA levels.
    explanation: The presence of HBsAg typically indicates active hepatitis B infection, as its absence in OBI is noted as unusual.
  - reference: PMID:22300111
    reference_title: "Diagnostic incidence of the presence of positive HBsAg: epidemiologic, clinical, and virological characteristics."
    supports: SUPPORT
    snippet: To analyze the epidemiological, clinical, and virological characteristics of patients newly diagnosed with active hepatitis B virus (HBV) infection based on the presence of positive hepatitis B surface antigen (HBsAg).
    explanation: The study focuses on diagnosing active hepatitis B infection by the presence of HBsAg.
- name: HBeAg Test
  description: Blood test detecting Hepatitis B e antigen, a marker of active viral replication and high infectivity.
  presence: Positive
  notes: Indicates high levels of viral replication
  evidence:
  - reference: PMID:25218700
    reference_title: "Occult hepatitis B virus infection with positive hepatitis B e antigen."
    supports: SUPPORT
    snippet: 'BACKGROUND: Hepatitis B e antigen (HBeAg) is a marker to indicate active replication of hepatitis B virus (HBV).'
    explanation: HBeAg is indeed a marker used to indicate active replication of HBV, supporting the statement that a positive HBeAg test indicates high levels of viral replication.
  - reference: PMID:20512987
    reference_title: "Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers."
    supports: PARTIAL
    snippet: HBeAg correlated with serum HBV DNA (r = 0.60, P < 0.0001), although emerging BCP/PC variants reduced HBeAg titer independent of viral replication.
    explanation: While HBeAg generally correlates with high levels of viral replication, there are instances where emerging viral variants can reduce HBeAg levels independent of viral replication, indicating that the correlation is not absolute.
  - reference: PMID:29869595
    reference_title: "Poor Sensitivity of Commercial Rapid Diagnostic Tests for Hepatitis B e Antigen in Senegal, West Africa."
    supports: PARTIAL
    snippet: Alternatively, HBV e antigen (HBeAg) may accurately indicate high viral replication.
    explanation: HBeAg can indicate high viral replication, but the prevalence of HBeAg in highly viremic patients was low, suggesting that not all high viral replication cases will test positive for HBeAg.
- name: HBV DNA Test
  description: PCR-based test that quantifies HBV DNA in blood to measure viral load.
  presence: Positive
  notes: Measures viral load in the blood
  evidence:
  - reference: PMID:12776281
    reference_title: "Biological dynamics of hepatitis B virus load in dialysis population."
    supports: SUPPORT
    snippet: HBV DNA was measured using the Amplicor HBV Monitor Test (Roche Diagnostics, Branchburg, NJ), an in vitro assay using polymerase chain reaction nucleic acid amplification and DNA hybridization for the quantitative measurement of HBV DNA in serum.
    explanation: This study confirms that the HBV DNA test measures viral load in the blood of hepatitis B patients.
  - reference: PMID:33453301
    reference_title: "Performance evaluation of Xpert HBV viral load (VL) assay: Point-of-care molecular test to strengthen and decentralize management of chronic hepatitis B (CHB) infection."
    supports: SUPPORT
    snippet: Estimation of hepatitis B (HBV) viral load (VL) is critical in hepatitis-B cascade-of-care and at present there is no point of care (POC) molecular assay available for the same.
    explanation: The study discusses the importance of estimating HBV viral load, which is done through testing HBV DNA.
  - reference: PMID:38163269
    reference_title: "Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA."
    supports: SUPPORT
    snippet: Accurate detection and quantification of HBV DNA in the blood are essential for diagnosing and monitoring HBV infection. The most common method for detecting HBV DNA is real-time PCR, which can be used to detect the virus and assess the viral load to monitor the response to antiviral therapy.
    explanation: This reference supports that the HBV DNA test measures viral load in the blood.
  - reference: PMID:32360825
    reference_title: "Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants."
    supports: SUPPORT
    snippet: We assessed the performance of a novel immunoassay, HBV core-related antigen (HBcrAg), as a low-cost (less than US $15/assay) alternative to nucleic acid testing to indicate clinically important high viremia in chronic HBV patients infected with different genotypes.
    explanation: The study mentions nucleic acid testing (which includes HBV DNA tests) as a method to measure viral load in the blood.
- name: Liver Biopsy
  description: Tissue sampling procedure to directly assess liver histology for inflammation, fibrosis, and cirrhosis.
  notes: Assesses liver damage and fibrosis
  evidence:
  - reference: PMID:17613355
    reference_title: "Liver biopsy assessment in chronic hepatitis."
    supports: SUPPORT
    snippet: Liver biopsy has been a major diagnostic tool in the evaluation of individuals with chronic hepatitis for many decades and remains the most direct way of visualizing hepatic necroinflammation and fibrosis.
    explanation: The reference clearly states that liver biopsy is a major diagnostic tool for visualizing hepatic necroinflammation and fibrosis, thus supporting the statement.
  - reference: PMID:35240329
    reference_title: "Baseline Hepatitis B Virus Surface Antigen Titers in Childhood Predict the Risk of Advanced Liver Fibrosis in Adulthood."
    supports: NO_EVIDENCE
    snippet: Transient elastography was performed at a mean final age of 38.21 years to identify advanced fibrosis.
    explanation: Although the primary focus is on transient elastography, the study context implies that liver biopsy is a standard method for assessing liver fibrosis.
  - reference: PMID:23808910
    reference_title: "Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B."
    supports: PARTIAL
    snippet: Present study was designed to correlate fibroscan with liver biopsy and determine whether fibroscan can avoid liver biopsy in patients with CHB.
    explanation: The study compares fibroscan with liver biopsy, indicating that liver biopsy is a standard method for assessing liver fibrosis.
  - reference: PMID:36458851
    reference_title: "Hepatitis delta virus: Disease assessment and stratification."
    supports: SUPPORT
    snippet: Liver biopsy remains the gold standard for staging of liver fibrosis and grading of histological activity and should remain central for diagnostic purposes.
    explanation: The reference confirms that liver biopsy is the gold standard for assessing liver fibrosis, supporting the statement.
environmental:
- name: Poor Sterile Practices
  description: Inadequate infection control in healthcare settings increases HBV transmission through contaminated needles, surgical instruments, and blood products.
  notes: Increases the risk of transmission via medical procedures
  environment_context:
    preferred_term: healthcare facility
    term:
      id: ENVO:03501134
      label: healthcare facility
  evidence:
  - reference: PMID:20123446
    reference_title: "US outbreak investigations highlight the need for safe injection practices and basic infection control."
    supports: SUPPORT
    snippet: Increasing recognition of outbreaks involving patient-to-patient spread of hepatitis B and hepatitis C virus infections, however, has uncovered a disturbing trend. This article highlights the importance of basic infection control and the need for increased awareness of safe injection practices.
    explanation: The article indicates that poor sterile practices can lead to patient-to-patient spread of hepatitis B, supporting the statement that poor sterile practices increase the risk of transmission via medical procedures.
  - reference: PMID:10840606
    reference_title: "[Transmission of HBV, HCV and HIV by infectious medical personnel--presentation of an overview]."
    supports: SUPPORT
    snippet: Cases with the highest number of transmissions (one anesthesiologist with 217 HC transmissions, and one EEG technologist with 75 HB transmissions) were attributed to poor infection control practices.
    explanation: The report documents numerous cases of hepatitis B transmission attributed to poor infection control practices, supporting the statement.
  - reference: PMID:23074317
    reference_title: "Transmission of hepatitis B virus from an orthopedic surgeon with a high viral load."
    supports: SUPPORT
    snippet: We documented HBV transmission during orthopedic surgery to 2 patients from a surgeon with HBV. This investigation highlights the importance of evaluating individuals who do not respond to 2 series of HBV vaccination, the increased risk of HBV transmission from providers with high viral loads, and the need to evaluate the clinical practice of providers with HBV and implement appropriate procedure-based practice restrictions.
    explanation: The study demonstrates that poor sterile practices and high viral loads in healthcare providers can lead to the transmission of hepatitis B during medical procedures.
- name: High-risk Behaviors
  description: Behavioral risk factors including unprotected sexual intercourse, intravenous drug use with shared needles, and occupational exposure to blood.
  notes: Includes unprotected sexual contact and intravenous drug use
  evidence:
  - reference: PMID:2183516
    reference_title: "Hepatitis B: transmission by sexual contact and needle sharing."
    supports: SUPPORT
    snippet: In the Western world most cases of hepatitis B virus (HBV) infection are acquired through sexual intercourse and through needle sharing by intravenous drug users (IVDU).
    explanation: The literature explicitly mentions that HBV infection is commonly acquired through sexual intercourse and needle sharing, which aligns with the statement's mention of unprotected sexual contact and intravenous drug use as high-risk behaviors.
  - reference: PMID:20411413
    reference_title: "HIV risk behaviors: risky sexual activities and needle use among adolescents in substance abuse treatment."
    supports: NO_EVIDENCE
    snippet: Sex with multiple partners, sex under the influence of alcohol or drugs, and unprotected sex were the most prevalent HIV risk behaviors.
    explanation: Although this reference primarily discusses HIV, it also notes that unprotected sex is a prevalent risk behavior, which supports the statement regarding high-risk behaviors for HBV.
  - reference: PMID:32338365
    reference_title: "Prevalence of hepatitis B and anti-hepatitis C virus antibody among people who inject drugs in the Lebanese population."
    supports: SUPPORT
    snippet: People who inject drugs (PWIDs) are prone to a number of blood-borne viral infections. Hepatitis B virus (HBV) and hepatitis C virus (HCV) constitute an important public health concern in this high risk group.
    explanation: The literature states that people who inject drugs are at high risk for HBV, supporting the statement that intravenous drug use is a high-risk behavior for HBV.
  - reference: PMID:27364104
    reference_title: "Risk of occupational exposure to the HBV infection in non-clinical healthcare personnel."
    supports: PARTIAL
    snippet: The possibility of the HBV infection risk during the exposure was found in 25 cases and was significantly more frequent in the group III.
    explanation: This reference indicates that exposure to HBV infection is a significant risk, supporting the statement of high-risk behaviors related to HBV.
treatments:
- name: Antiviral Medications
  description: Includes drugs like tenofovir and entecavir to suppress HBV replication.
  evidence:
  - reference: PMID:26732483
    reference_title: "Recent developments in antivirals against hepatitis B virus."
    supports: SUPPORT
    snippet: Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have been recommended as the first-line anti-HBV drugs for excellent viral suppression with a low risk of antiviral resistance.
    explanation: The reference explicitly mentions tenofovir and entecavir as first-line drugs for suppressing HBV replication.
  - reference: PMID:26054819
    reference_title: "The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists."
    supports: SUPPORT
    snippet: Since 2008, it has also been indicated for treatment of chronic HBV infection or HIV/HBV co-infection. The aim of the treatment consists in suppressing viral replication, thus reducing hepatic complications and improving patient survival.
    explanation: The reference supports the use of tenofovir for suppressing HBV replication.
  - reference: PMID:32050881
    reference_title: "[Evaluation of Histological Response in Chronic Hepatitis B Patients with Tenofovir or Entecavir Therapy]."
    supports: SUPPORT
    snippet: The aim of this study was to evaluate the histological, virological, serological and biochemical response rates in CHB patients receiving tenofovir or entecavir therapy.
    explanation: The study evaluates the effects of tenofovir and entecavir in CHB patients, supporting their role in HBV suppression.
  - reference: PMID:27742007
    reference_title: "Hepatitis B Virus Infection and Liver Decompensation."
    supports: PARTIAL
    snippet: This is achievable by the highly active antivirals, entecavir and tenofovir, which are considered first-line therapy in most patients with immune active hepatitis C virus and after liver transplantation to prevent HBV recurrence.
    explanation: The reference confirms that tenofovir and entecavir are used to suppress HBV replication.
  treatment_term:
    preferred_term: antiviral therapy
    term:
      id: MAXO:0000168
      label: antiviral agent therapy
- name: Interferon Therapy
  description: Boosts the immune system to fight the virus.
  evidence:
  - reference: PMID:25034484
    reference_title: "Interferon therapy of chronic hepatitis B."
    supports: PARTIAL
    snippet: Interferon-alpha (IFN-alpha) therapy can convert CHB into inactive hepatitis B virus (HBV) infection in 20-30% of the treated patients...IFN-alpha has multiple antiviral, antiproliferative, and immunomodulatory activities.
    explanation: The literature indicates that Interferon-alpha has immunomodulatory activities, which can help in controlling HBV infection, but it does not explicitly state that it 'boosts' the immune system in the general sense.
  - reference: PMID:16461223
    reference_title: "Immune system and hepatitis B virus infection."
    supports: PARTIAL
    snippet: Therapeutic strategies aimed at correcting this defective T cell reactivity could represent a complementary approach to the cure of chronic HBV infection.
    explanation: The literature suggests that targeting immune responses is a strategy in treating HBV, but it does not explicitly state that Interferon Therapy 'boosts' the immune system.
  - reference: PMID:10804945
    reference_title: "Chronic hepatitis B virus in children in Israel: clinical and epidemiological characteristics and response to interferon therapy."
    supports: PARTIAL
    snippet: We found IFN to be a safe and adequate mode of treatment in children with chronic HBV infection, regardless of their liver histology and transaminase levels.
    explanation: The study indicates that Interferon Therapy is effective in treating HBV in children, but it does not explicitly state that it 'boosts' the immune system.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
- name: Liver Transplant
  description: For end-stage liver disease.
  evidence:
  - reference: PMID:29125261
    reference_title: "Hepatitis B and liver transplantation."
    supports: SUPPORT
    snippet: Liver transplantation (LT) is the only effective treatment for hepatitis B-virus (HBV) related end stage liver disease...
    explanation: This reference explicitly states that liver transplantation is the only effective treatment for end-stage liver disease caused by hepatitis B.
  - reference: PMID:17981234
    reference_title: "Hepatitis B and end-stage liver disease."
    supports: PARTIAL
    snippet: Until recently, the options for a patient who had end-stage hepatitis B cirrhosis were severely limited, but during the past 15 years great strides have been made in prevention and treatment of hepatitis B cirrhosis.
    explanation: The reference discusses the advancements in treatment options for end-stage hepatitis B cirrhosis, implying liver transplantation as a viable option.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
- name: Regular Monitoring
  description: Monitoring liver function and viral load to manage chronic infection.
  evidence:
  - reference: PMID:24266913
    reference_title: "Chronic hepatitis B virus infection."
    supports: SUPPORT
    snippet: Chronically infected patients should be followed on a regular basis, preferably every 6 months, with liver function tests, and when appropriate, HBV DNA levels.
    explanation: The literature supports regular monitoring of liver function and viral load in patients with chronic hepatitis B infection.
  - reference: PMID:12776281
    reference_title: "Biological dynamics of hepatitis B virus load in dialysis population."
    supports: PARTIAL
    snippet: Periodic testing for HBV DNA to assess the virological status of HBsAg-positive dialysis patients is recommended.
    explanation: The study recommends regular monitoring of viral load in hepatitis B patients, supporting the statement.
  - reference: PMID:33467927
    reference_title: "Monitoring hepatitis B by using point-of-care testing: biomarkers, current technologies, and perspectives."
    supports: PARTIAL
    snippet: This manuscript summarized traditional biomarkers of different hepatitis B stages and recent-developed POCT platforms (including microfluidic platforms and lateral-flow strips) and discuss the challenges associated with their use.
    explanation: The article discusses the importance of monitoring hepatitis B using various biomarkers, which aligns with the statement.
  - reference: PMID:31528100
    reference_title: "On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B."
    supports: SUPPORT
    snippet: HBcrAg is an excellent monitor of hepatic histological changes, especially in CHB patients treated with nucleoside analogs.
    explanation: The literature highlights the importance of monitoring liver-related biomarkers in chronic hepatitis B patients.
  - reference: PMID:26799653
    reference_title: "Hepatitis B: treatment choice and monitoring for response and resistance."
    supports: SUPPORT
    snippet: As a result, regular monitoring of the response during treatment and after treatment is required.
    explanation: The article emphasizes the necessity of regular monitoring in the management of chronic hepatitis B.
  - reference: PMID:33945063
    reference_title: "Characteristics Associated with Monitoring and Treatment of Chronic Hepatitis B in a Large Cohort of Australian Adults."
    supports: SUPPORT
    snippet: Regular monitoring and treatment of chronic hepatitis B (CHB) are known to reduce the risk of hepatocellular carcinoma.
    explanation: The literature supports regular monitoring as a vital part of managing chronic hepatitis B to reduce complications.
- name: Vaccination
  description: Hepatitis B vaccine provides prevention for uninfected individuals.
  evidence:
  - reference: PMID:10776195
    reference_title: "Hepatitis B vaccine."
    supports: SUPPORT
    snippet: Immunization of all newborn infants and adolescents for HBV is a vital step toward eradicating HBV from the general population.
    explanation: The article supports the statement by emphasizing the importance of immunizing infants and adolescents to prevent HBV infection.
  - reference: PMID:33200362
    reference_title: "Prevention of Hepatitis B Virus Infection and Liver Cancer."
    supports: SUPPORT
    snippet: Primary prevention by HBV vaccination targeting the general population starting from birth dose.
    explanation: The article confirms that HBV vaccination is a primary prevention strategy for the general population.
  - reference: PMID:17298912
    reference_title: "A review of the long-term protection after hepatitis A and B vaccination."
    supports: SUPPORT
    snippet: Hepatitis B vaccines have been licensed since 1982... Long-term protection has been demonstrated.
    explanation: The article discusses the long-term protection conferred by hepatitis B vaccines, supporting their role in preventing HBV infection.
  - reference: PMID:22643598
    reference_title: "Hepatitis B vaccine: prophylactic, therapeutic, and diagnostic dilemma."
    supports: SUPPORT
    snippet: Hepatitis B is a preventable disease; a safe and effective vaccine has been available for 30 years.
    explanation: The article states that hepatitis B is preventable through vaccination, supporting the statement.
  - reference: PMID:19187625
    reference_title: "Vaccination against hepatitis B: the Chinese experience."
    supports: SUPPORT
    snippet: The chronic HBV carrier rate in children < 10 years of age decreased from 10.0% before the mass vaccination to 1.0% - 2.0% in 2006.
    explanation: The article provides evidence from China's mass vaccination program, showing a significant reduction in HBV carrier rates due to vaccination.
  treatment_term:
    preferred_term: vaccination
    term:
      id: MAXO:0001017
      label: vaccination
review_notes: Enhanced pathophysiology section based on 2024 research including NTCP receptor mechanism, cccDNA formation, HBx protein function, DNA integration pathways, immune evasion mechanisms (TLR, cGAS-STING dampening), and T cell exhaustion with checkpoint receptor upregulation. Added GO biological process terms for viral entry, DNA integration, epigenetic regulation, and immune checkpoint pathways. Expanded cell type annotations including Kupffer cells and regulatory T cells. Added locations field consistently using UBERON terms as per schema requirements.
disease_term:
  preferred_term: hepatitis B virus infection
  term:
    id: MONDO:0005344
    label: hepatitis B virus infection
📚

References & Deep Research

Deep Research

2
Disorder ▸

Disorder

  • Name: Hepatitis B
  • Category: Infectious Disease
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 160

Key Pathophysiology Nodes

  • Hepatocyte Infection and cccDNA Formation
  • HBV DNA Integration
  • Chronic Inflammation
  • Immune Evasion and T Cell Exhaustion
  • Liver Fibrosis
  • Cirrhosis
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1080/21505594.2024.2421231
  • DOI:10.1099/jgv.0.001978
  • DOI:10.11575/prism/46732
  • DOI:10.1186/s40364-024-00611-y
  • DOI:10.20944/preprints202408.1996.v1
  • DOI:10.3389/fimmu.2025.1506526
  • DOI:10.3390/ph17070964
  • DOI:10.3390/v16091361
Falcon ▸
Pathophysiology description
Edison Scientific Literature 32 citations 2025-12-15T09:21:29.529873

Pathophysiology description

Hepatitis B virus (HBV) is a partially double-stranded DNA virus that infects hepatocytes and establishes a persistent nuclear reservoir of covalently closed circular DNA (cccDNA), enabling chronic infection and predisposing to cirrhosis and hepatocellular carcinoma (HCC) (allweiss2024highlightsfromthe pages 2-5, zhang2024epigeneticmodificationof pages 1-2). Entry is mediated by the large HBV surface protein preS1 binding the hepatocyte bile acid transporter NTCP (SLC10A1), which is now a clinically validated antiviral target; bulevirtide blocks this preS1–NTCP interaction to prevent viral entry (URL: https://doi.org/10.1099/jgv.0.001978, May 2024) (allweiss2024highlightsfromthe pages 2-5).

Following entry and uncoating, the relaxed circular viral DNA (rcDNA) is transported to the nucleus and converted by host DNA repair factors into cccDNA, which forms a chromatinized minichromosome that templates transcription of all viral RNAs, including pregenomic RNA (pgRNA) and the regulatory X protein (HBx) (URL: https://doi.org/10.3390/v16091361, Aug 2024; URL: https://doi.org/10.1080/21505594.2024.2421231, Nov 2024) (li2024hepatitisbviral pages 1-3, zhang2024epigeneticmodificationof pages 1-2). A fraction (~5–10%) of nucleocapsid reverse transcription products are double-stranded linear DNA (dslDNA), which can integrate at sites of host DNA damage; integrated HBV DNA contributes to persistent HBsAg expression and oncogenesis (URL: https://doi.org/10.3390/ph17070964, Jul 2024; URL: https://doi.org/10.1186/s40364-024-00611-y, Aug 2024) (costa2024insightsintoimmune pages 4-5, zhang2024theimpactof pages 1-2).

HBV has evolved strategies to limit innate detection (“stealth virus” behavior) in hepatocytes and the liver microenvironment by dampening TLR signaling, suppressing cGAS–STING and RIG-I–MAVS pathways, and inducing tolerogenic cytokines (e.g., IL-10); adaptive responses progressively exhibit T cell exhaustion with high PD-1, CTLA-4, and TIM-3 expression, particularly within the liver (URL: https://doi.org/10.11575/prism/46732, Jul 2024; URL: https://doi.org/10.1099/jgv.0.001978, May 2024; URL: https://doi.org/10.3390/ph17070964, Jul 2024) (patel2024investigatingtheunique pages 31-38, allweiss2024highlightsfromthe pages 2-5, costa2024insightsintoimmune pages 4-5). HBx supports viral replication and contributes to hepatocarcinogenesis by rewiring host transcription, epigenetics, and survival pathways (URL: https://doi.org/10.3390/v16091361, Aug 2024; URL: https://doi.org/10.1080/21505594.2024.2421231, Nov 2024) (li2024hepatitisbviral pages 1-3, zhang2024epigeneticmodificationof pages 1-2).

HBV DNA integration is present in the vast majority of HBV-related HCCs (≈85–90%) and can drive oncogenesis through insertional mutagenesis, structural rearrangements, and activation of proto-oncogenes (e.g., TERT, MYC), often coupled with loss of tumor suppressors (e.g., TP53) (URL: https://doi.org/10.1186/s40364-024-00611-y, Aug 2024; preprint URL: https://doi.org/10.20944/preprints202408.1996.v1, Aug 2024) (zhang2024theimpactof pages 1-2, georgi2024understandinghepatitisb pages 5-6). Clinically, interferon-α can suppress replication and modulate cccDNA epigenetics but has limited overall efficacy and tolerability; nucleos(t)ide analogues (NUCs) suppress viremia though they do not eliminate cccDNA. IFN-based and NUC therapies lower HCC risk, and IFN may reduce new integration events (allweiss2024highlightsfromthe pages 2-5, zhang2024theimpactof pages 1-2).

Gene/protein annotations with ontology terms (HGNC, GO) and roles

  • SLC10A1 (NTCP) [HGNC:11039]: Hepatocyte bile acid transporter; high-affinity HBV receptor enabling preS1-mediated entry; pharmaceutical target for bulevirtide (GO:0046718 viral entry into host cell) (allweiss2024highlightsfromthe pages 2-5).
  • MB21D1 (cGAS) [HGNC:26727] and TMEM173 (STING) [HGNC:30868]: Cytosolic DNA sensing and signaling (GO:0061761 cGAS–STING signaling pathway) partially active in hepatocytes; targeted by HBV immune evasion (zhang2024epigeneticmodificationof pages 1-2, allweiss2024highlightsfromthe pages 2-5).
  • MAVS [HGNC:29895] and TLRs (e.g., TLR4 [HGNC:11850]): RNA/DNA sensing adaptors; HBV components dampen TLR signaling and downstream IFN cascades (patel2024investigatingtheunique pages 31-38).
  • PDCD1 (PD-1) [HGNC:17635], CTLA4 [HGNC:2505], HAVCR2 (TIM-3) [HGNC:18437]: Immune checkpoints upregulated on HBV-specific T cells, mediating exhaustion and impaired control (GO:0050868 negative regulation of T cell activation) (costa2024insightsintoimmune pages 4-5).
  • HBx (viral protein X): Multifunctional regulator that activates viral transcription from cccDNA and promotes oncogenic programs through epigenetic remodeling and signaling crosstalk (GO:0040029 epigenetic regulation of gene expression) (li2024hepatitisbviral pages 1-3, zhang2024epigeneticmodificationof pages 1-2).
  • DNA integration (process) (GO:0015074): HBV dslDNA integrates into host genome, driving structural variants and oncogenesis (zhang2024theimpactof pages 1-2, georgi2024understandinghepatitisb pages 5-6).
Entity Type / Ontology ID Role in HBV Pathophysiology Key Evidence (PMID/DOI with year)
SLC10A1 (NTCP) HGNC HGNC:11039 Hepatocyte bile-acid transporter that serves as the high-affinity receptor for HBV/HDV preS1-mediated entry; therapeutic target of entry inhibitor bulevirtide DOI:10.1099/jgv.0.001978 (2024) (allweiss2024highlightsfromthe pages 2-5)
MB21D1 (cGAS) HGNC HGNC:26727 Cytosolic dsDNA sensor that activates STING to induce type I IFNs and innate antiviral responses against HBV-derived DNA DOI:10.1099/jgv.0.001978 (2024) (allweiss2024highlightsfromthe pages 2-5)
TMEM173 (STING) HGNC HGNC:30868 Adaptor downstream of cGAS that drives interferon/ inflammatory signaling and modulates hepatocyte innate responses to HBV DNA DOI:10.1080/21505594.2024.2421231 (2024) (zhang2024epigeneticmodificationof pages 1-2)
MAVS HGNC HGNC:29895 Mitochondrial adaptor for RIG-I-like receptors; part of RNA sensing pathways that can be antagonized during HBV infection DOI:10.11575/prism/46732 (2024) (patel2024investigatingtheunique pages 31-38)
TLR4 HGNC HGNC:11850 Toll-like receptor implicated in innate sensing; HBV antigens (HBsAg/HBeAg) can dampen TLR signaling contributing to immune evasion DOI:10.11575/prism/46732 (2024) (patel2024investigatingtheunique pages 31-38)
PDCD1 (PD-1) HGNC HGNC:17635 Immune checkpoint upregulated on HBV-specific T cells during chronic infection → T cell exhaustion and impaired viral clearance DOI:10.3390/ph17070964 (2024) (costa2024insightsintoimmune pages 4-5)
CTLA4 HGNC HGNC:2505 Co-inhibitory receptor contributing to suppressed T cell activation in chronic HBV DOI:10.3390/ph17070964 (2024) (costa2024insightsintoimmune pages 4-5)
HAVCR2 (TIM-3) HGNC HGNC:18437 Inhibitory receptor associated with exhausted intrahepatic T cells in CHB and HBV-related HCC microenvironment DOI:10.3390/ph17070964 (2024) (costa2024insightsintoimmune pages 4-5)
Hepatocyte Cell Ontology (CL) CL:0000182 Primary HBV target cell where entry (NTCP), rcDNA→cccDNA conversion, cccDNA minichromosome maintenance, and viral transcription occur DOI:10.20944/preprints202408.1996.v1 (2024) (georgi2024understandinghepatitisb pages 5-6)
Kupffer cell Cell Ontology (CL) CL:0000863 Liver-resident macrophage that captures incoming virions and shapes early innate responses in the hepatic microenvironment DOI:10.1099/jgv.0.001978 (2024) (allweiss2024highlightsfromthe pages 2-5)
CD8+ T cell Cell Ontology (CL) CL:0000625 Effector cells mediating cytolytic clearance; become functionally exhausted (PD-1/TOX/LAG3) in chronic HBV, reducing viral control DOI:10.3390/ph17070964 (2024) (costa2024insightsintoimmune pages 4-5)
NK cell Cell Ontology (CL) CL:0000623 Innate lymphocyte with antiviral activity; phenotype/function modulated (e.g., NKG2A upregulation) during HBV, contributing to impaired early control DOI:10.11575/prism/46732 (2024) (patel2024investigatingtheunique pages 31-38)
Regulatory T cell (Treg) Cell Ontology (CL) CL:0000815 FoxP3+ population enriched in CHB liver microenvironment that promotes immune tolerance and viral persistence DOI:10.20944/preprints202408.1996.v1 (2024) (georgi2024understandinghepatitisb pages 5-6)
Liver Uberon UBERON:0002107 Anatomical site of HBV replication, immune interactions, inflammation, fibrosis and HCC development DOI:10.1099/jgv.0.001978 (2024) (allweiss2024highlightsfromthe pages 2-5)
Taurocholate (bile acid) ChEBI CHEBI:36276 Endogenous NTCP substrate; NTCP's bile-acid transport function is mechanistically linked to HBV/HDV preS1 docking and to entry-inhibitor pharmacology DOI:10.1099/jgv.0.001978 (2024) (allweiss2024highlightsfromthe pages 2-5)
Interferon-alpha ChEBI CHEBI:28729 Immunomodulatory therapy (peg-IFN-α) that can reduce HBV replication and modulate cccDNA epigenetics but has limited efficacy and tolerability DOI:10.20944/preprints202408.1996.v1 (2024), DOI:10.1186/s12985-024-02589-3 (2024) (georgi2024understandinghepatitisb pages 5-6, zheng2025theroleof pages 2-3)
Entecavir ChEBI CHEBI:50671 Nucleos(t)ide RT inhibitor that suppresses HBV DNA replication (>95% virologic suppression in compliant patients) but does not eliminate cccDNA DOI:10.3390/ph17070964 (2024) (costa2024insightsintoimmune pages 4-5)
Tenofovir disoproxil ChEBI CHEBI:63638 Potent nucleos(t)ide analog suppressing HBV replication; long-term therapy lowers HCC incidence but does not clear cccDNA DOI:10.3390/ph17070964 (2024) (costa2024insightsintoimmune pages 4-5)
viral entry into host cell GO Biological Process GO:0046718 Process describing viral attachment/entry (NTCP–preS1 interaction central for HBV hepatocyte infection) DOI:10.1099/jgv.0.001978 (2024) (allweiss2024highlightsfromthe pages 2-5)
cGAS-STING signaling pathway GO Biological Process GO:0061761 Innate DNA-sensing cascade (cGAS→STING) that can detect HBV DNA and induce type I IFNs, but is variably active in hepatocytes and targeted by viral evasion DOI:10.1080/21505594.2024.2421231 (2024) (zhang2024epigeneticmodificationof pages 1-2)
DNA integration GO Biological Process GO:0015074 Insertion of HBV-derived dslDNA into host genome → insertional mutagenesis, structural rearrangements (e.g., TERT/chr8q) and oncogenesis in HCC DOI:10.1186/s40364-024-00611-y (2024) (zhang2024theimpactof pages 1-2)
epigenetic regulation of gene expression GO Biological Process GO:0040029 Host chromatin and epigenetic modifiers regulate cccDNA minichromosome activity and HBV transcription; HBx influences epigenetic states promoting persistence/HCC DOI:10.1080/21505594.2024.2421231 (2024) (zhang2024epigeneticmodificationof pages 1-2)
negative regulation of T cell activation GO Biological Process GO:0050868 Checkpoint and immunoregulatory processes (PD-1/CTLA-4/TIM-3, Tregs, IL-10) that suppress HBV-specific T cell responses, facilitating chronicity DOI:10.3390/ph17070964 (2024) (costa2024insightsintoimmune pages 4-5)

Table: Concise ontology mappings of key genes, cells, chemicals and GO processes involved in Hepatitis B pathophysiology, with primary evidence DOIs and context citations to support knowledge-base annotation.

Phenotype associations (HP terms)

  • Acute/chronic hepatitis with elevated transaminases, jaundice, and hepatomegaly; progression to fibrosis, cirrhosis, portal hypertension, and HCC. These clinical manifestations reflect immune-mediated hepatocyte injury rather than direct cytopathic effects (allweiss2024highlightsfromthe pages 2-5, zhang2024epigeneticmodificationof pages 1-2).

Cell type involvement (CL terms)

  • Hepatocyte (CL:0000182): Site of entry, rcDNA→cccDNA conversion, minichromosome formation, and viral gene expression (georgi2024understandinghepatitisb pages 5-6).
  • Kupffer cell (CL:0000863): Rapidly captures incoming virions, shaping early intrahepatic innate responses (allweiss2024highlightsfromthe pages 2-5).
  • CD8+ T cell (CL:0000625): Central for viral clearance; chronically becomes exhausted (PD-1high TIM-3high) intrahepatically (costa2024insightsintoimmune pages 4-5).
  • NK cell (CL:0000623): Innate antiviral function blunted via increased inhibitory receptors (e.g., NKG2A) and immunosuppressive milieu (patel2024investigatingtheunique pages 31-38).
  • Regulatory T cell (CL:0000815): Enriched intrahepatically; promotes tolerance and persistence (georgi2024understandinghepatitisb pages 5-6).

Anatomical locations (UBERON terms)

  • Liver (UBERON:0002107): Primary infection site; chronic inflammation, fibrosis, and oncogenesis (allweiss2024highlightsfromthe pages 2-5).

Chemical entities (CHEBI terms) and therapeutics

  • Taurocholate (CHEBI:36276): Endogenous NTCP substrate; receptor function links bile acid transport to HBV entry (allweiss2024highlightsfromthe pages 2-5).
  • Interferon-alpha (CHEBI:28729): Immunomodulator that suppresses replication and may impact cccDNA epigenetics; limited efficacy and tolerability (georgi2024understandinghepatitisb pages 5-6, allweiss2024highlightsfromthe pages 2-5).
  • Entecavir (CHEBI:50671), Tenofovir disoproxil (CHEBI:63638): First-line NUCs suppress viremia but spare cccDNA; reduce HCC risk (costa2024insightsintoimmune pages 4-5).

1. Core Pathophysiology

  • Primary mechanisms: preS1–NTCP binding mediates hepatocyte entry; rcDNA→cccDNA conversion establishes a stable, chromatinized minichromosome that drives all viral transcription; HBx enhances cccDNA transcriptional activity and modulates host pathways (allweiss2024highlightsfromthe pages 2-5, li2024hepatitisbviral pages 1-3, zhang2024epigeneticmodificationof pages 1-2).
  • Dysregulated pathways: innate DNA/RNA sensing (cGAS–STING, TLRs, MAVS) suppressed by HBV products; adaptive immunity shows T cell exhaustion with elevated checkpoints and impaired effector function (patel2024investigatingtheunique pages 31-38, costa2024insightsintoimmune pages 4-5).
  • Affected cellular processes: chromatin/epigenetic regulation of cccDNA transcription; integration of dslDNA causing genomic instability; immune checkpoints limiting T cell activation; tolerance-promoting cytokines (zhang2024epigeneticmodificationof pages 1-2, zhang2024theimpactof pages 1-2, costa2024insightsintoimmune pages 4-5, patel2024investigatingtheunique pages 31-38).

2. Key Molecular Players

  • Genes/Proteins: NTCP/SLC10A1 (entry receptor), HBx (regulator/oncogenic cofactor), cGAS (MB21D1), STING (TMEM173), MAVS, TLR4; PD-1/PDCD1, CTLA-4, TIM-3/HAVCR2 (allweiss2024highlightsfromthe pages 2-5, li2024hepatitisbviral pages 1-3, zhang2024epigeneticmodificationof pages 1-2, costa2024insightsintoimmune pages 4-5, patel2024investigatingtheunique pages 31-38).
  • Chemical Entities: bile acids (e.g., taurocholate) linking NTCP function and entry; IFN-α; NUCs (entecavir, tenofovir) (allweiss2024highlightsfromthe pages 2-5, georgi2024understandinghepatitisb pages 5-6, costa2024insightsintoimmune pages 4-5).
  • Cell Types: hepatocytes, Kupffer cells, CD8+ T cells, NK cells, regulatory T cells (allweiss2024highlightsfromthe pages 2-5, costa2024insightsintoimmune pages 4-5, patel2024investigatingtheunique pages 31-38, georgi2024understandinghepatitisb pages 5-6).
  • Anatomical Locations: liver (allweiss2024highlightsfromthe pages 2-5).

3. Biological Processes (GO terms) disrupted

  • Viral entry into host cell (GO:0046718): NTCP–preS1 interaction (allweiss2024highlightsfromthe pages 2-5).
  • cGAS–STING signaling pathway (GO:0061761): attenuated in hepatocytes and targeted by HBV evasion (zhang2024epigeneticmodificationof pages 1-2).
  • DNA integration (GO:0015074): dslDNA integration drives insertional mutagenesis and oncogenesis (zhang2024theimpactof pages 1-2, georgi2024understandinghepatitisb pages 5-6).
  • Epigenetic regulation of gene expression (GO:0040029): governs cccDNA minichromosome activity and HBx effects (zhang2024epigeneticmodificationof pages 1-2, li2024hepatitisbviral pages 1-3).
  • Negative regulation of T cell activation (GO:0050868): checkpoint-mediated exhaustion in chronic infection (costa2024insightsintoimmune pages 4-5).

4. Cellular Components

  • Plasma membrane (NTCP localization) for docking/entry; nucleus (cccDNA minichromosome, epigenetic control); mitochondria (MAVS platform); endosomes (TLR signaling); extracellular space (HBsAg virions/subviral particles) (allweiss2024highlightsfromthe pages 2-5, zhang2024epigeneticmodificationof pages 1-2, patel2024investigatingtheunique pages 31-38).

5. Disease Progression

  • Sequence: Entry via NTCP → nuclear rcDNA→cccDNA formation → viral transcription/replication → early innate evasion in hepatocytes and tolerogenic microenvironment → chronic antigenemia (HBsAg/HBeAg) and T/NK cell dysfunction (exhaustion) → chronic hepatitis with inflammatory flares and fibrosis → integration events accumulate, genomic instability and clonal selection → HCC (allweiss2024highlightsfromthe pages 2-5, patel2024investigatingtheunique pages 31-38, zhang2024theimpactof pages 1-2).
  • Phases: Immune tolerant HBeAg+ phase (often perinatal infections), immune active phase, HBeAg-negative phase with fluctuating viremia/inflammation; occult infection can persist with reactivation risk under immunosuppression (patel2024investigatingtheunique pages 31-38, allweiss2024highlightsfromthe pages 2-5).

6. Phenotypic Manifestations

  • Clinical phenotypes: asymptomatic carriage to chronic hepatitis with ALT/AST elevations, jaundice, hepatomegaly; progression to fibrosis/cirrhosis, portal hypertension, hepatic decompensation, and HCC; immune-mediated hepatocyte injury predominates over direct cytopathicity (allweiss2024highlightsfromthe pages 2-5, zhang2024epigeneticmodificationof pages 1-2).

Recent developments (2023–2024), applications, expert opinions, and data

  • Entry and NTCP targeting: International HBV Meeting 2023 highlights the centrality of NTCP for entry and clinical translation of entry inhibitors, reinforcing bulevirtide’s mechanism (Journal of General Virology, May 2024; DOI above) (allweiss2024highlightsfromthe pages 2-5).
  • cccDNA and epigenetic control: 2024 reviews emphasize epigenetic regulation of cccDNA activity and HBx as a key transcriptional activator, underscoring therapeutic strategies to silence cccDNA transcription (Virulence, Nov 2024; DOI above) (zhang2024epigeneticmodificationof pages 1-2).
  • Immune evasion/exhaustion: 2024 analyses synthesize evidence for suppressed innate sensors (TLR, cGAS–STING, MAVS) and chronic T cell exhaustion with checkpoint upregulation in intrahepatic compartments, rationalizing immunotherapeutic combinations (Pharmaceuticals, Jul 2024; thesis Jul 2024) (costa2024insightsintoimmune pages 4-5, patel2024investigatingtheunique pages 31-38).
  • Integration and HCC: 2024 review quantifies integration in ≈85–90% of HBV-HCCs and details oncogenic mechanisms, including activation of TERT and genomic rearrangements; expert opinion pieces stress that clearing cccDNA and integrated DNA is required for sterilizing cure (Biomarker Research, Aug 2024; preprint Aug 2024) (zhang2024theimpactof pages 1-2, georgi2024understandinghepatitisb pages 5-6).
  • Global burden and statistics: 2019 prevalence ≈4.1% (~316 million) and hundreds of thousands of deaths; WHO 2022 estimates ≈254 million living with chronic HBV, with low treatment uptake in those diagnosed (Virulence, Nov 2024; Frontiers in Immunology, Mar 2025) (zhang2024epigeneticmodificationof pages 1-2, zheng2025theroleof pages 2-3).

Evidence items and URLs (publication dates)

  • Allweiss L. et al. Highlights from the 2023 International HBV Meeting. Journal of General Virology. May 2024. URL: https://doi.org/10.1099/jgv.0.001978 (allweiss2024highlightsfromthe pages 2-5).
  • Zhang Y. et al. Epigenetic modification of HBV infection and related HCC. Virulence. Nov 2024. URL: https://doi.org/10.1080/21505594.2024.2421231 (zhang2024epigeneticmodificationof pages 1-2).
  • Li D., Tu T. Hepatitis B Viral Protein HBx: Roles in Viral Replication and Hepatocarcinogenesis. Viruses. Aug 2024. URL: https://doi.org/10.3390/v16091361 (li2024hepatitisbviral pages 1-3).
  • Zhang M. et al. Impact of integrated HBV DNA on oncogenesis and antiviral therapy. Biomarker Research. Aug 2024. URL: https://doi.org/10.1186/s40364-024-00611-y (zhang2024theimpactof pages 1-2).
  • Costa J.P. et al. Immune exhaustion in CHB: checkpoint receptor expression. Pharmaceuticals. Jul 2024. URL: https://doi.org/10.3390/ph17070964 (costa2024insightsintoimmune pages 4-5).
  • Patel N.H. Investigating immunological and virological characteristics of HBV in special populations. University of Calgary thesis. Jul 2024. URL: https://doi.org/10.11575/prism/46732 (patel2024investigatingtheunique pages 31-38).
  • Georgi C. et al. Understanding HBV persistence: mechanisms, consequences and implications for cure. Preprint. Aug 2024. URL: https://doi.org/10.20944/preprints202408.1996.v1 (georgi2024understandinghepatitisb pages 5-6).
  • Zheng H. et al. Role of immune regulation in HBV infection and hepatocarcinogenesis. Frontiers in Immunology. Mar 2025. URL: https://doi.org/10.3389/fimmu.2025.1506526 (zheng2025theroleof pages 2-3).

Expert analysis

  • Consensus across recent expert reports emphasizes that a functional cure (HBsAg loss and DNA suppression off-therapy) remains the near-term objective, while sterilizing cure will require targeting both cccDNA and integrants. Combination approaches that couple direct antivirals (e.g., entry inhibitors, NUCs, RNAi) with immunomodulation (checkpoint inhibition, TLR agonists) and epigenetic silencing of cccDNA are a rational path forward (allweiss2024highlightsfromthe pages 2-5, zhang2024epigeneticmodificationof pages 1-2, zhang2024theimpactof pages 1-2).

Current applications and real-world implementations

  • Entry inhibition: Bulevirtide clinically validates NTCP as a drug target and, mechanistically, confirms preS1–NTCP as the essential entry axis for HBV/HDV (allweiss2024highlightsfromthe pages 2-5).
  • Antivirals: Long-term NUC therapy achieves >95% suppression of viremia in adherent patients but requires sustained administration given the persistence of cccDNA; IFN-α remains finite but limited by tolerability; both reduce HCC risk (costa2024insightsintoimmune pages 4-5, allweiss2024highlightsfromthe pages 2-5).

References within text (supporting specific claims)

  • Entry/NTCP, cccDNA persistence, non-cytopathicity, clinical biomarker relevance of HBsAg: (allweiss2024highlightsfromthe pages 2-5).
  • Epigenetic regulation of cccDNA, HBx functions in oncogenesis: (zhang2024epigeneticmodificationof pages 1-2, li2024hepatitisbviral pages 1-3).
  • Innate immune evasion (TLRs, cGAS–STING, MAVS) and stealth phenotype; NK/T cell dysfunction: (patel2024investigatingtheunique pages 31-38, allweiss2024highlightsfromthe pages 2-5, costa2024insightsintoimmune pages 4-5).
  • Integration burden and oncogenic consequences including TERT activation and structural rearrangements; implications for cure: (zhang2024theimpactof pages 1-2, georgi2024understandinghepatitisb pages 5-6).
  • Global burden (2019 and 2022 estimates) and low treatment coverage: (zhang2024epigeneticmodificationof pages 1-2, zheng2025theroleof pages 2-3).

"HBV infection establishes a long-lived cccDNA reservoir; spontaneous or clinical resolution often fails to eradicate infection because cccDNA persists" (allweiss2024highlightsfromthe pages 2-5). "HBV integration is detected in ~85–90% of HBV-associated HCCs and contributes to oncogenesis via genomic instability and dysregulation of cancer genes" (zhang2024theimpactof pages 1-2).

References

  1. (allweiss2024highlightsfromthe pages 2-5): Lena Allweiss, Chari Cohen, Joao Dias, Valeria Fumagalli, Haitao Guo, James M. Harris, Jianming Hu, Matteo Iannacone, Masanori Isogawa, Wen-Juei Jeng, Kyun-Hwan Kim, Anna Kramvis, Wenhui Li, Julie Lucifora, Masamichi Muramatsu, Christine Neuveut, Alexander Ploss, Teresa Pollicino, Ulrike Protzer, Anthony Tan, Yasuhito Tanaka, Thomas Tu, Senko Tsukuda, Robert Thimme, Stephan Urban, Koichi Watashi, Zhenghong Yuan, Shiou-Hwei Yeh, Jane A. McKeating, and Peter A. Revill. Highlights from the 2023 international meeting on the molecular biology of hepatitis b virus. Journal of General Virology, May 2024. URL: https://doi.org/10.1099/jgv.0.001978, doi:10.1099/jgv.0.001978. This article has 0 citations and is from a peer-reviewed journal.

  2. (zhang2024epigeneticmodificationof pages 1-2): Yaqin Zhang, Weihua Cao, Shiyu Wang, Lu Zhang, Xinxin Li, Ziyu Zhang, Yao Xie, and Minghui Li. Epigenetic modification of hepatitis b virus infection and related hepatocellular carcinoma. Virulence, Nov 2024. URL: https://doi.org/10.1080/21505594.2024.2421231, doi:10.1080/21505594.2024.2421231. This article has 15 citations and is from a peer-reviewed journal.

  3. (li2024hepatitisbviral pages 1-3): Dong Li, Yassir Hamadalnil, and Thomas Tu. Hepatitis b viral protein hbx: roles in viral replication and hepatocarcinogenesis. Viruses, 16:1361, Aug 2024. URL: https://doi.org/10.3390/v16091361, doi:10.3390/v16091361. This article has 30 citations and is from a poor quality or predatory journal.

  4. (costa2024insightsintoimmune pages 4-5): João Panão Costa, Armando de Carvalho, Artur Paiva, and Olga Borges. Insights into immune exhaustion in chronic hepatitis b: a review of checkpoint receptor expression. Pharmaceuticals, 17:964, Jul 2024. URL: https://doi.org/10.3390/ph17070964, doi:10.3390/ph17070964. This article has 12 citations and is from a poor quality or predatory journal.

  5. (zhang2024theimpactof pages 1-2): Mingming Zhang, Han Chen, Huan Liu, and Hong Tang. The impact of integrated hepatitis b virus dna on oncogenesis and antiviral therapy. Biomarker Research, Aug 2024. URL: https://doi.org/10.1186/s40364-024-00611-y, doi:10.1186/s40364-024-00611-y. This article has 17 citations and is from a peer-reviewed journal.

  6. (patel2024investigatingtheunique pages 31-38): Nishi Harishkumar Patel. Investigating the unique immunological and virological characteristics of hepatitis b in special populations. Other, Jul 2024. URL: https://doi.org/10.11575/prism/46732, doi:10.11575/prism/46732. This article has 1 citations.

  7. (georgi2024understandinghepatitisb pages 5-6): Christopher Georgi, Carla S. Coffin, and Curtis Cooper. Understanding hepatitis b virus (hbv) persistence: mechanisms, consequences and implications for cure. Aug 2024. URL: https://doi.org/10.20944/preprints202408.1996.v1, doi:10.20944/preprints202408.1996.v1.

  8. (zheng2025theroleof pages 2-3): Hailong Zheng, Bingchen Xu, Yiyu Fan, Aekkachai Tuekprakhon, Zania Stamataki, and Fei Wang. The role of immune regulation in hbv infection and hepatocellular carcinogenesis. Frontiers in Immunology, Mar 2025. URL: https://doi.org/10.3389/fimmu.2025.1506526, doi:10.3389/fimmu.2025.1506526. This article has 6 citations and is from a peer-reviewed journal.